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ABSTRACT 
Bats asymptomatically host a number of viruses that are the cause of recently 
emergent infectious diseases in humans. While the mechanisms underlying this 
asymptomatic infection are currently not known, studies of sequenced bat genomes help 
uncover genetic adaptations in bats that may have functional importance in the antiviral 
response of these animals. To identify differences between antiviral mechanisms in 
humans and bats, we sequenced, assembled, and analyzed the genome of the Egyptian 
rousette bat (ERB; Rousettus aegyptiacus), a natural reservoir of Marburg virus and the 
only known reservoir for any filovirus. We used this genome to understand the evolution 
of immune genes and gene families in bats, and describe several observations relevant to 
defense against viruses. 
We observed an unusual expansion of the NKG2/CD94 natural killer (NK) cell 
receptor gene families in Egyptian rousette bats relative to other species, and found 
genomic evidence of unique features and expression of these receptors that may result in 
  ix
a net inhibitory balance within bat NK cells. The expansion of NK cell receptors is 
matched by an expansion of potential major histocompatibility complex (MHC) class I 
ligands, which are distributed both within and, surprisingly, outside the canonical MHC 
loci. We also observed that the type I interferon (IFN) locus is considerably expanded 
and diversified in the ERB, and that the IFN-ω subfamily contributes most to this 
expansion. To understand the functional implications of this expansion, we synthesized 
multiple IFN-ω proteins and examined their antiviral effects. Members of this subfamily 
are not constitutively expressed but are induced after viral infection, and show antiviral 
activity in vitro, with different antiviral potencies observed for different IFN-ω proteins.  
Taken together, these results show that multiple bats, including the ERB, have 
expanded and diversified numerous antiviral loci, and potentially developed unique 
adaptations in NK cell receptor signaling, and type I IFN responses. The concerted 
evolution of so many key components of immunity in the ERB is strongly suggestive of 
novel modes of antiviral defense that may contribute to the ability of bats to 
asymptomatically host viruses that are pathogenic in humans. 
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CHAPTER ONE: INTRODUCTION 
Portions of this chapter are © 2018 Elsevier Inc. and were originally published in 
Pavlovich, et al, “The Egyptian Rousette Genome Reveals Unexpected Features of Bat 
Antiviral Immunity” Cell (2018), DOI: https://doi.org/10.1016/j.cell.2018.03.070. 
Marburg virus disease 
History and epidemiology 
 Marburg virus (MARV) is a negative-sense nonsegmented RNA virus (order 
Mononegavirales; family Filoviridae) with a generally filamentous shape and a cell-
derived membrane that is decorated with viral glycoprotein. The negative-sense genome 
encodes genes for seven structural viral proteins, including the glycoprotein (GP), the 
polymerase (L), the nucleoprotein (NP), the matrix protein (VP40), and three additional 
nucleocapsid proteins (VP24, VP30, and VP35) (Brauburger et al. 2012; Yamaoka et al. 
2017; Olejnik et al. 2017). MARV causes Marburg virus disease (MVD), a severe 
systemic disease with high viral loads and high case-fatality rates (Brauburger et al. 
2012). It was first reported in 1967 when laboratory workers in multiple European cities 
developed similar symptoms, including fever, rash, and hemorrhage, after handling tissue 
from infected cynomologus macaques that were imported from Uganda (Slenczka 2017). 
Though MVD is relatively uncommon compared to other endemic diseases, its 
epidemiological importance is underscored by its potential to cause large and devastating 
outbreaks, as has been seen for Ebola virus disease (EVD). Since 1967, the history of 
MVD has mostly been characterized by numerous small outbreaks. However, most of the 
reported cases of MVD were in association with two major outbreaks in the Democratic 
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Republic of Congo and Angola, with case-fatality rates of 83-90% (CDC 2014; Wasswa 
2017). The devastating impact of MVD has prompted attempts to define areas that might 
be at risk for future outbreaks, and mathematical modeling has identified as many as 27 
countries in Africa at risk (Pigott et al. 2015). Additionally, as both the 1967 MVD 
outbreak and the 2013-2016 Ebola outbreak in West Africa have shown, the rapid spread 
of infection outside of endemically at-risk areas is certainly possible (Bausch 2017). Also 
of ecological concern is the potential for filovirus-mediated wildlife mortality, where 
populations of intermediate hosts like non-human primates (NHPs) can be dramatically 
reduced after filovirus-infection in the wild. This has mainly been observed for EVD, but 
remains a concern for MVD (Amman et al. 2017). 
Clinical features of MVD 
 The sporadic nature of reported MVD outbreaks (13 in total, most recently in late 
2017) (CDC 2014; Wasswa 2017) suggests that spillover events from reservoir or 
intermediate hosts are the instigating factor, but human-to-human transmission of the 
virus remains the main cause of infection during outbreaks (Amman et al. 2017). Data 
from both MVD and EVD outbreaks indicates that transmission occurs by contact with 
infected body fluids or close contact with infected patients or animals, after which the 
virus can enter through breaks in the skin or mucous membranes (Brauburger et al. 2012; 
Muñoz-Fontela & McElroy 2017). The incubation period of the virus is thought to range 
from 3 to 21 days, and in previous EVD and MVD outbreaks, patients generally sought 
medical care roughly four or five days after the onset of symptoms (Brauburger et al. 
2012; Slenczka 2017; Muñoz-Fontela & McElroy 2017). RT-PCR and qRT-PCR assays 
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(detecting VP40 and NP mRNA), as well as ELISA (antigen capture and IgG/IgM 
detection) on blood and serum samples, have all been successfully used for diagnosis 
(Grolla et al. 2011; Towner et al. 2006).  
Three phases of illness have been defined for both EVD and MVD with many 
similarities between them, though MVD more commonly features hemorrhagic 
symptoms (Muñoz-Fontela & McElroy 2017). The first phase consists of non-specific 
symptoms common to many infections, including fever, malaise, headache, and muscle 
pain. This is followed by the second phase, where high fever can persist, and multiple 
organ systems may be effected; neurological (encephalitis, delirium), gastrointestinal 
(diarrhea, melena, liver damage, hematemesis), and commonly hemorrhagic symptoms 
(gastrointestinal bleeding, bleeding from venipuncture sites, bruising, petechial rash) 
occur. Patients either enter a convalescence phase or succumb to disseminated 
intravascular coagulation, shock, and/or multi-organ system failure and subsequent death 
just a few weeks after the onset of symptoms (Brauburger et al. 2012; Muñoz-Fontela & 
McElroy 2017). 
Pathology and immune response in Marburg virus infection 
 Most of what is known regarding filovirus-associated disease in humans is based 
on data from patients with EVD rather than MVD (Muñoz-Fontela & McElroy 2017), 
though there are several common threads that are corroborated by NHP models, and 
autopsy specimens from the 1967 MVD outbreak have also been studied. In both 
diseases, dendritic cells, monocytes, and macrophages are thought to be infected early on, 
and the liver, lymph nodes, and spleen are known to be major sites of viral replication, 
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likely because of the circulation and high density of monocyte-derived cells within these 
tissues (Brauburger et al. 2012). Nearly every tissue is infected late in the disease course. 
Lymphocytes are not known to be susceptible to filovirus infection; however, lymphocyte 
apoptosis and lymphocytolysis have been observed in certain NHP models of MVD 
(Fernando et al. 2015; Lin et al. 2015), especially within germinal centers. The relative 
changes in T cell and natural killer (NK) cell numbers in various tissues such as the 
spleen suggest that some of the observed cell count decreases may be due to trafficking 
of these cells to different compartments (Fritz et al. 2008).  
 Though in vitro studies have shown that MARV and EBOV inhibit innate 
immune responses, NHP models of disease, and some patient data, point to immune 
activation rather than inhibition. Fatal EVD in humans is associated with high levels of 
inflammatory cytokines, including IL-6 and IP-10 (Muñoz-Fontela & McElroy 2017). 
This is also the case in NHP models and MVD NHP models, though cytokine data from 
MARV-infected patients are not available (Fernando et al. 2015; Alves et al. 2010). This 
cytokine upregulation is believed to be a result of viral replication since it is also 
observed (and subsequently downregulated) in asymptomatic filovirus-infected humans 
(Leroy et al. 2001; Leroy et al. 2000). 
 Fatal EVD in humans has also been associated with type I interferon (IFN) 
signatures (Liu et al. 2017), though the role of IFN responses in filovirus-mediated 
disease is still unresolved. An intact IFN response is necessary for surviving infection in 
mouse models, but in uniformly lethal NHP models, MARV infection leads to a robust 
IFN-like response in circulating PBMCs (Brauburger et al. 2012; Connor et al. 2015; 
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Caballero et al. 2014). Understanding the IFN response is further complicated by the 
potentially divergent roles and induction of different IFN subtypes. In some studies, large 
serum IFN-α values are observed in NHPs that eventually succumb to infection (Fritz et 
al. 2008), yet IFN-β pre-treatment prolongs survival in infected animals (Smith et al. 
2013). In the same study, delaying the IFN response with a monoclonal antibody to the 
IFNAR1 subunit of the IFN receptor decreased survival time, suggesting that IFNs are 
important to the response and cannot simply be inhibited to prevent immune 
dysregulation. Thus, the role of IFNs in filoviral pathogenesis remains unresolved. An 
understanding of the downstream ISGs that may contribute to filovirus restriction is also 
limited. A few ISGs are known to inhibit filoviruses during fusion (IFITMs), translation 
(ZAP), and potentially in other ways (ISG15), and others are actively inhibited by 
filovirus proteins or have no effect on viral replication (Olejnik et al. 2017; Diamond & 
Farzan 2013). However, most of the hundreds of effectors that make up the IFN response 
remain uncharacterized in terms of their specific activity against filoviruses.  
 
Treatment and vaccination 
 There are currently no licensed treatments or vaccines for any filovirus, though 
this is mostly because of the difficulty of conducting clinical trials in outbreak settings. 
However, many treatments and vaccines have been developed, and efficacy in animal 
models has been demonstrated for many of them. Several strategies have been used for 
filovirus vaccines, including virus-like particles (VLPs), DNA-based and viral vector 
vaccines, inactivated virus, and recombinant virus-based vaccines. Most of these have 
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been shown to work with 100% efficacy in mouse and macaque models of disease, which 
is encouraging because of higher fatality rates in these models (Reynolds & Marzi 2017). 
The only exceptions are inactivated viruses and some DNA-based vaccines, which have 
subsequently been improved with modifications to codon-optimize plasmids (Brauburger 
et al. 2012; Reynolds & Marzi 2017). Promising vaccine candidates for EVD and/or 
MVD include the recombinant vesicular stomatitis virus (VSV) encoding filoviral GP 
(rVSVΔG-EBOV-GP), the chimpanzee type 3 adenovirus expressing EBOV GP (ChAd3-
EBO Z), and DNA plasmid vaccines (VRC-EBODNA023-00-VP and VRC-
MARDNA025-00-VP) are currently being explored in clinical trials (Higgs et al. 2017; 
Halperin et al. 2017; Kibuuka et al. 2015). 
Clinical management of MVD and EVD largely consists of supportive care, 
especially replacing lost fluids, managing life-threatening electrolyte imbalances and 
clotting disorders, and treating symptoms. Care includes antidiarrheals, antiemetics, renal 
replacement therapy, rhythm correction, and supplemental oxygen or mechanical 
ventilation, among other therapy (Sprecher et al. 2017; Marshall Lyon et al. 2017). In 
low-resource settings, both symptomatic care and ruling out/treating co-infections with 
other endemic pathogens are important (Sprecher et al. 2017). 
 Many experimental post-exposure therapeutics have been identified and tested in 
animal models, though clinical trials to test safety and efficacy testing have been difficult 
to design in outbreak settings. Potential therapeutics include those that target the virus or 
host factors, as well as antibody-based therapies. Several small molecules have been 
identified that target virus entry by interacting with the cholesterol transport pathway or 
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the entry receptor Niemann-Pick type C 1 protein (Connor et al. 2017). Nucleoside 
analogs, substrates for the viral RNA-dependent RNA polymerase, have been developed 
to block viral replication and transcription (Warren et al. 2014). Antivirals originally 
developed for treating other viral infections, like favipiravir, have also been shown to 
increase survival in MARV-infected NHPs when given intravenously  (Bixler et al. 2018; 
Delang et al. 2018). There is some efficacy evidence for post-exposure therapy with 
hyperimmune serum, but this therapy has not achieved much success in patients because 
of improperly controlled trials (Dye et al. 2016; Dye et al. 2012; Connor et al. 2017). 
Monoclonal antibodies (mAbs) targeting filoviral proteins are of great interest, and 
additional work is being done to mine for and generate mAbs that avoid viral escape 
mutants (Kugelman et al. 2015). 
Bats as hosts of viral pathogens 
Ecology and evolution of bats 
Bats are members of the order Chiroptera, the second-most species-diverse 
mammalian order after Rodentia. Chiroptera consists of two suborders; the, 
Yinpterochiroptera suborder contains all bats morphologically classified as megabats 
(family: Pteropodidae), as well as multiple families of microbats (Rhinolophoid 
microbats), while all remaining microbats belong to the Yangochiroptera suborder 
(Teeling et al. 2005).  
Bats are also known to host a number of viruses that cause recently emergent 
infectious diseases in other mammals. These viruses include human pathogens with the 
potential to cause devastating outbreaks; they cause severe diseases (with high case-
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fatality rates) for which little to no specific treatment is available. In particular, certain 
species of bats are known to host Nipah and Hendra viruses (NiV and HeV), rabies virus, 
Severe acute respiratory syndrome- and Middle East respiratory syndrome coronaviruses 
(SARS-CoV and MERS-CoV), and MARV, among others. HeV, a negative-stranded 
RNA virus, was first observed in 1994 when an unexplained severe respiratory illness 
affected a number of thoroughbred horses and their handlers in Queensland, Australia. 
After a second outbreak of HeV in another location the virus was eventually traced to 
pteropid bats that migrated between the two outbreak sites. When closely related NiV 
caused an outbreak of encephalitis in humans and pigs in Malaysia in 1998, bats were 
surveilled and virus was again found in pteropid bats (Field et al. 2001; Rahman et al. 
2010; Chua et al. 2002). 
SARS-CoV was initially traced to civets in open markets in China, and bat meat 
in the same markets was thought to be a source of the virus before transmission to civets. 
Subsequent studies showed that multiple species of horseshoe bats were seropositive and 
PCR-positive for a coronavirus that was phylogenetically clustered with strains of SARS-
CoV (Li et al. 2005). Similarly, in the case of MARV, multiple cases of MVD have been 
epidemiologically linked to exposure to Egyptian rousettes (Egyptian fruit bats; ERBs; 
species: Rousettus. aegyptiacus); bats in multiple locations are seropositive for MARV, 
and the virus has been isolated from bats infected in the wild (Towner et al. 2009; 
Towner et al. 2007; Amman et al. 2012). Bats are also suspected to be a natural reservoir 
host for EBOV, though viral isolation studies for EBOV have been less conclusive 
(Amman et al. 2017; Schuh et al. 2017c).  
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Genomic approaches to studying bat immunology 
The stark difference between disease severity in humans and bats after viral 
infection has motivated efforts to characterize the genes involved in the immune system 
of bats and understand the antiviral immune mechanisms used to control viral infection. 
A number of bat genomes and transcriptomes have been sequenced and annotated to 
provide a foundation for these studies and studies of other remarkable traits in bats, 
including longevity, echolocation, and flight. These genome projects have used a number 
of different sequencing chemistries, including Sanger sequencing and high-throughput 
next-generation sequencing (NGS) with various library preparation strategies. Genomic 
analyses of immune genes in bats have produced conflicting and surprising observations. 
Of the available bat genomes, the most thoroughly studied is that of the Australian black 
flying fox (Pteropus alecto) (Papenfuss et al. 2012; Zhang et al. 2013), a reservoir host of 
HeV. Additional bat genomes have been studied to a more limited extent (Seim et al. 
2013; Zhang et al. 2013; Parker et al. 2013).  
The most notable findings from these studies involve two large classes of immune 
genes: NK cell receptors, and type I IFNs. Multiple studies have reported the absence of 
canonical NK cell receptors in bat genomes (Shaw et al. 2012; Zhang et al. 2013; Lee et 
al. 2015), though a few receptors were identified in the P. alecto transcriptome 
(Papenfuss et al. 2012). A few studies suggest that significant differences exist in type I 
IFNs between bats and humans (Zhang et al. 2017; Zhou et al. 2016; Kepler et al. 2010; 
De La Cruz-Rivera et al. 2018), though the precise nature of the differences remains 
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unclear.  For example, the type I IFN locus has contracted in Pteropus alecto (Zhou et al. 
2016), but expanded in Pteropus vampyrus and Myotis lucifugus (Kepler et al. 2010). 
Other immune regions in bat genomes have also been examined, including the 
MHC region, the immunoglobulin locus, and genes associated with innate immune 
responses. These studies have generally observed that most of these loci are conserved 
between bats and other mammals, with few exceptions like smaller genomic size, and 
increased diversity in antigen receptors (Ng et al. 2016; Ng et al. 2017; Butler et al. 2011; 
Papenfuss et al. 2012). Genomic information has been used to study gene evolution; 
evidence of positive selection pressures has been identified in genes involved in pathogen 
recognition, antiviral effector function, and DNA damage response (Zhang et al. 2013; 
Fuchs et al. 2017; Jiang et al. 2017).  
Current knowledge and challenges 
Findings from bat genome projects have served as the foundation for in vitro 
experimental work to investigate various pathways that could limit viral pathogenicity in 
bats. The majority of these studies have focused on virus susceptibility and entry, and 
innate immunity, with a particular emphasis on pathways related to IFNs. With regard to 
viral entry, multiple groups have shown that cell lines from both suborders of bats are 
susceptible to infection by multiple RNA viruses, though SARS coronaviruses seem to be 
an exception (Hoffmann et al. 2013; Miller et al. 2016). With regard to filoviruses, 
reduced infectivity has been observed in some bat cell lines with some filovirus species 
(Hoffmann et al. 2013; Ng et al. 2015; Hoffmann et al. 2016). For example, EBOV 
infection of African straw-colored fruit bat (Eidolon helvum) cell lines is limited at the 
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entry level because of mutations in the NPC1 receptor (Ng et al. 2015). Similarly, RoNi/7 
cells, derived from kidney tissue from an adult Egyptian rousette, show 1 to 1.5 logs less 
luciferase activity in VSV-filovirus GP pseudotype assays compared to Vero E6 or 
HEK293T cells (Hoffmann et al. 2016; Hoffmann et al. 2013). These results could be 
explained by a deficit in entry; however, VSV-G controls were also less efficient in RoNi 
cells than in Vero cells in this assay, possibly reflecting a nonspecific reduction of viral 
replication rather than impaired entry. Collectively, these studies indicate that no clear 
limitation in entry is discernable in bat cells (with the exception of EBOV in E. helvum) 
but subtle differences in entry efficiency between bat cells and human or NHP cells may 
be responsible for limiting viral infection to a small degree.  
The second major focus of in vitro work based on bat genome studies is innate 
immune function, especially type I, II, and III IFN pathways. Both primary and 
immortalized cells from multiple bat species retain pattern recognition receptors (Cowled 
et al. 2012; Cowled et al. 2011; Jiang et al. 2017) and express type I and type III IFNs 
after transfection with a mimetic of dsRNA (poly I:C) or infection with VSV, Newcastle 
disease virus, and other viruses. (Kepler et al. 2010; Virtue et al. 2011; Zhou et al. 2011; 
Biesold et al. 2011; Glennon et al. 2015). In contrast, antagonism of IFN production was 
observed after infection with henipaviruses and Tioman virus (Virtue et al. 2011; Zhou et 
al. 2011).  
Bat cells also retain responsiveness to exogenous universal IFN (UIFN; a pan-
species type I IFN derived from two human IFN-αs), recombinant bat IFN-β and IFN-αs 
(Zhang et al. 2017; De La Cruz-Rivera et al. 2018; Zhou et al. 2016), as well as 
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supernatants from cells expressing bat IFNs. Bat cells pretreated with these IFN stimuli 
have been shown to have antiviral activity against influenza A virus, VSV, yellow fever 
virus, pteropine orthoreovirus (PRV1NB), and filoviruses (Biesold et al. 2011; Zhou et al. 
2016; Zhang et al. 2017; De La Cruz-Rivera et al. 2018; Kuzmin et al. 2017). Other IFN 
subtypes have been studied to a more limited extent. IFN-κ and IFN-ω from the European 
serotine bat (Eptesicus serotinus) have been shown to inhibit lyssavirus infections  in 
vitro (He et al. 2014).  
Consistent with the observed antiviral function, UIFN, recombinant bat IFN-β and 
IFN-αs, and supernatants from cells expressing bat IFNs have all been shown to stimulate 
the production of ISGs, though some differences have been observed in the level of 
induction of particular ISGs, with IFN-β classically inducing much higher expression 
(Zhou et al. 2016; De La Cruz-Rivera et al. 2018; He et al. 2014). While many IFNs and 
IFN related genes are conserved between bats and other mammals, there are a few 
notable exceptions, including differences among bat species. For example, one group 
recently reported a contraction of the type I IFN locus in the black flying fox (Pteropus 
alecto), which is a natural reservoir for henipaviruses (Zhou et al. 2016). Targeted 
sequencing revealed only 11 type I IFN genes in P. alecto, compared to 17 in humans, 
with 3 IFN-α genes, 5 IFN-ω genes, and 1 of each of the IFN-β, -ε, and -κ genes. In 
contrast, expansions of the type I IFN locus have been reported in P. vampyrus and M. 
lucifugus (Kepler et al. 2010). Similarly, IFN-α is constitutively expressed in multiple 
tissues in P. alecto, but not in R. aegyptiacus (Zhou et al. 2016; Kuzmin et al. 2017). 
IRF7, which in humans is constitutively expressed only in specialized immune cells like 
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plasmacytoid dendritic cells, appears to be expressed in multiple tissues in P. alecto and 
may drive constitutive IFN-α expression (Zhou et al. 2014). UIFN and IFN-α3 
stimulation of P. alecto cell lines induces some ISGs that are not induced by IFN in 
humans, and the response kinetics of ISG induction in bats may vary from that in humans 
as well (De La Cruz-Rivera et al. 2018; Zhang et al. 2017).  
Studying diverse bat genomes provides insight into common immune mechanisms 
among bats that make them suitable hosts for emerging viruses. However, the insights 
into immune genes gained from previously assembled bat genomes are limited by the 
contiguity of these genomes. Immune gene families are known to have high rates of 
turnover in numerous species, and undergo gene conversion and other complex 
evolutionary events (Oren et al. 2016; Barreiro & Quintana-Murci 2010). As a result, 
immune genes often exist in multiple, diversified, yet closely-related copies in repetitive 
genomic loci. These duplicated genes may provide a dosage advantage to the host, and 
also serve as a source for the evolution of genes with new or specialized functions (Lynch 
& Conery 2000). Available bat genomes are either low-coverage or only use short-read 
next-generation sequencing technologies, both of which make it difficult to resolve 
highly repetitive immune loci (Ng et al. 2016; Zhang et al. 2013). 
Though existing genome studies have made available some tools for investigating 
bat immunology, findings for one bat may not be applicable to all bats. This is in part 
because different bat species do not serve as reservoirs for the same zoonotic viruses. Co-
evolution of a bat host species with a given viral pathogen could result in immune 
adaptations that are unique to that particular species of bat. A few bat genome studies 
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have already shown that particular immune loci are present in some bats but not others 
(Zhang et al. 2013; Baker et al. 2013). With regard to functional studies, much of the 
work has been done in P. alecto cell lines since the most resources are available for this 
species. However, even the limited number of studies in additional bats have shown that 
findings cannot be generalized across all species in the remarkably diverse Chiropteran 
order (Biesold et al. 2011; Kuzmin et al. 2017; Hoffmann et al. 2016; Ng et al. 2015).  
Additional bat genomes, especially high contiguity genomes, are needed to facilitate this 
work. 
Rousettus aegyptiacus 
Ecology and epidemiology 
MVD is a zoonotic disease, and it is believed that spillover events from a natural 
reservoir or intermediate host are the main triggers for human infection. During the 1998-
2000 MARV outbreak in the Democratic Republic of the Congo and subsequent smaller 
scale MARV spillover events in Uganda, systematic surveillance of the animals that were 
inhabiting affected mines and caves resulted in PCR and antibody evidence linking 
Egyptian rousettes (Egyptian fruit bats; ERBs, species: Rousettus aegyptiacus) to MARV 
(Amman et al. 2017). Genetically diverse viruses were subsequently isolated from ERBs 
in Kitaka mine in Uganda over a period of many months, confirming that ERBs could 
serve as a long-term reservoir (Towner et al. 2009). 
ERBs are echolocating fruit bats belonging to the Yinpterochiroptera suborder, 
and are spread over many African countries, especially in central and south central Africa 
(Kwiecinski & Griffiths 1999; Brauburger et al. 2012). ERBs roost in caves in 
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populations of up to 100,000 animals, with up to 5% of animals actively infected at a 
given time (Towner et al. 2009), though culling attempts in Kitaka resulted in an active 
infection rate of 13.7% (Amman et al. 2017). Spillover events from bats to humans 
(possibly via intermediate hosts like NHPs) have been hypothesized to happen 
seasonally, with an increase in the percentage of actively infected older juvenile bats 
during the biannual birthing seasons (Amman et al. 2012; Hayman 2015). 
Current knowledge and immune studies 
In experimental MARV inoculation, ERBs are viremic for up to a week with low 
viral titers. Multiple ERBs have been observed to shed the virus orally and rectally while 
sustaining a few focal liver lesions but no other observable morbidities (Paweska et al. 
2015; Jones et al. 2015; Amman et al. 2015). All bats eventually develop virus-specific 
IgG antibodies within a week or two. However, in studies designed to model natural 
infection among bats, bats that are ‘naturally’ infected by other experimentally inoculated 
bats appear to have a protracted incubation period (Amman et al. 2015; Schuh et al. 
2017a). Further, these studies showed that infected bats can remain viremic and shed 
infectious virus for extended periods of time (up to three weeks after infection) before 
eventually clearing the virus [Figure 1.1].  
Viral titers in ERBs range between 103 to 104 TCID50/mL in the blood (Schuh et 
al. 2017b; Amman et al. 2015), which is much lower than in NHPs (107 to 108 pfu/mL) 
(Lin et al. 2015; Alves et al. 2010). However, some patterns of virus distribution are 
common to NHPs and ERBs; just as in NHPs, in ERBs the liver and spleen are the first 
sites of viral replication, with higher viral loads than the blood, though multiple tissues 
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sustain viral replication. Transmission among bats likely occurs via oral secretions that 
may be transmitted without direct contact between bats or by biting/fighting behavior, 
though virus is also found in urine and fecal secretions (Amman et al. 2015; Schuh et al. 
2017c, Schuh et al. 2017b). Oral secretions contain higher viral titers than blood, and oral 
shedding of virus can occur up to four days after virus is cleared from the blood (Amman 
et al. 2015; Schuh et al. 2017b). Long-term studies of protective immunity show that 
antibody levels in infected bats drop below the threshold of seropositivity within a few 
months of infection, but repeat challenge results in an intact secondary immune response 
(Schuh et al. 2017b). This is consistent with the observation that virus does not persist in 
individual animals, and additionally supports the assumption that ERB populations serve 
as reservoirs because of seasonal inoculation of older juvenile animals. 
Despite prolonged infection, limited inflammation is observed in even the most 
highly infected tissues in ERBs (Amman et al. 2015; Schuh et al. 2017b), similar to what 
was previously observed in infected wild-caught bats (Jones et al. 2015; Towner et al. 
2009). In addition, viral titers in ERBs are remarkably low (105 to 106 TCID50/g eq in the 
most infected tissues) compared to NHPs and humans. The mechanisms by which this 
occurs are not known. The innate antiviral immunity of this bat has not been extensively 
studied, mainly because of a lack of reagents. One study in which two type I IFNs were 
sequenced has been published, albeit without functional studies (Omatsu et al. 2008). 
However, some tools are now available for experimental investigation. Multiple cell lines 
exist for in vitro studies: R0E6 (generated from fetal body tissue), R05T (generated from 
fetal head tissue), R05R (generated from fetal vertebrate column tissue)—all 
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immortalized by transfection of human adenovirus E1A and E1B genes (Jordan et al. 
2009)—and RoNi/7 (generated from adult kidney tissue), which was immortalized via 
lentiviral transduction of the large T antigen of SV40 (Biesold et al. 2011). These cell 
lines have been used for a few preliminary studies; Biesold et al. (2011) showed that the 
RoNi/7 cell line is able to produce and respond to type I IFN. Kuzmin et al (2017) 
transfected bat IFN-β, IFN-γ, and a consensus IFN-α into R0E6-J cells and RoNi/7 cells 
and observed the induction of ISG54 and ISG56 by qRT-PCR. IFN-α and -β transfection 
also increased IFN-λ expression. Both cell lines were able to resist EBOV and MARV 
infection upon transfection with type I or type II IFNs. In the same study, human cells 
expressed ISG54 and ISG56 when transfected with bat type I IFNs, but were unable to 
resist filovirus infection, highlighting that other ISGs are responsible for the viral 
resistance observed in transfected bat cell lines. Unlike what was observed in P. alecto 
(Zhou et al. 2016), R. aegyptiacus cell lines do not appear to express IFN-α genes 
constitutively (Kuzmin et al. 2017).  
Other groups have attempted to examine immune responses in a more high-
throughput way. In addition to a baseline transcriptome from multiple bat tissues (Lee et 
al. 2015), two groups have assembled transcriptomes from infected bat cell lines (Kuzmin 
et al. 2017; Hölzer et al. 2016). Kuzmin and colleagues found that MARV but not EBOV 
infection resulted in ISG induction in both R0E6-J and RoNi/7 cells. When the 
interferon-inhibiting domains in EBOV VP35 and VP24 were disabled, ISGs were 
induced. Hölzer and colleagues did not find a strong transcriptional response in R0E6-J 
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cells infected with EBOV or MARV, but this may be related to the lack of replicates or 
the use of purified virus. 
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Figure 1.1 Viral load and oral shedding in experimentally infected Egyptian 
rousette bats.  
Meta-analyses of previous 28-day studies of Egyptian rousette bats infected with a low 
passage bat-derived MARV isolate (Amman, et al. 2015 and Schuh, et al. 2017b). Blood 
and saliva samples were collected at the indicated days post-infection (DPI) for qRT-PCR 
quantitation of viral loads (expressed as log TCID50 equivalent units/mL), which were 
then averaged across the two studies (orange boxes for viremia and blue diamonds for 
shedding). The number of MARV-positive bats per day for either sample type is 
indicated by respective color at the bottom; for any day with more than one MARV-
positive bat, log standard error was calculated. Two-period moving average trendlines 
overlay each sample type dataset. Figure made by Jonathan C. Guito. 
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Current challenges 
There is no available reference genome for the ERB, which limits the ability to 
study MARV in its natural host because recombinant genetic methods for manipulating 
the immune system depend on genomic information. The lack of a reference genome also 
prevents detailed study of the evolutionary changes and the molecular mechanisms that 
allow bats of this species to coexist with MARV because orthologous genes cannot be 
identified and studied. Accurate and species-specific gene annotations are vital for 
designing reagents such as primers and antibodies to perform gene expression, protein 
quantification, and cytometry assays, especially since limited cross-reactivity has been 
observed for many such reagents (Kuzmin et al. 2017). To overcome this problem, a few 
transcriptome projects have been initiated for ERBs, but these projects have relied on de 
novo transcript assembly and are only able to capture genes that may be expressed under 
the specific conditions and in the specific tissues used for RNA isolation. Thus, in 
samples from uninfected bats, many genes that are only induced in response to infection 
remain uncharacterized.  
 
Scientific proposal and hypothesis 
Bats represent a diverse group of mammalian species and are known to 
asymptomatically host a number of viruses that are responsible for recently emergent 
infectious diseases, yet it remains unclear what allows bats to be productively infected 
without getting sick. This unusual trait in bats has motivated efforts to deeply 
characterize immune genes in bats and understand potentially unique antiviral immune 
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mechanisms that bats may use to control viral infection. One hypothesis that has been 
gaining acceptance is that bats present especially potent innate antiviral defenses 
compared to primates, controlling viral replication early in infection, and as a result, 
developing effective adaptive immune responses (Baker et al. 2013). However, this 
hypothesis has not been extensively supported by functional studies. Multiple groups 
have put together bat genome projects to begin to address this question by generating 
hypotheses and bat-specific reagents based on genetic information. These genomes have 
led to a number of experimental studies in certain species of bats, but the considerable 
diversity among bats limit the extension of the findings to all bats that serve as viral 
reservoirs. In addition, the sequencing strategies chosen for these genomes limit the 
ability to resolve repetitive genome loci where important immune gene loci reside.  
We aimed to develop genomic tools to facilitate studies of ERBs, which are a 
natural reservoir of MARV and the only known reservoir for any filovirus. We 
hypothesized that a hybrid sequencing approach making use of long- and short-read 
sequencing technologies would allow us to overcome some of the limitations in resolving 
immune gene loci. With this approach we sequenced, assembled, and annotated the ERB 
genome. Given the differences in geographic distribution between ERBs and other bat 
reservoirs, as well as differences between the viruses they host, we hypothesized that 
evolutionary pressures would results in major genomic differences between ERBs and 
other bats. We asked whether these differences occur at the gene and gene family level 
and whether they pertain to immune responses that may be relevant for surviving viral 
infection. Using the genome sequence, we investigate some of these differences by 
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examining genetic data and gene expression patterns across a range of bat tissues. This 
topic is addressed in Chapters Three and Four. 
It has been suggested that the severe pathogenesis of MARV in NHPs and 
humans might be attributed to the massive release of inflammatory cytokines, which 
results in immune dysregulation (Brauburger et al. 2012; Connor et al. 2015). In vitro and 
in vivo studies point to the type I IFN pathway as a key host-pathogen interface in which 
complex host-specific differences determine pathogenesis (Brauburger et al. 2012). The 
IFN response is an important first line of defense against viral invasion, and, because it 
represents a clear site of genetic divergence in mammals (Secombes & Zou 2017), it may 
play an important role in bat viral resistance or disease tolerance.  
Our genetic analysis described in Chapters Three and Four suggested that the type 
I IFNs have evolved in a unique manner in ERBs by expanding to more than 40 
members. We asked whether these genetic observations have functional implications for 
the antiviral immune response in ERBs. To address this question, we synthesized 
multiple bat IFNs and studied their antiviral function. We pretreated both primary and 
immortalized ERB cells with these recombinant proteins and characterized the resulting 
transcriptional responses, as well as their antiviral potency and efficacy. We hypothesized 
that the expansion of the IFN-ω subfamily could provide flexibility in constructing IFN 
responses, particularly if different IFN-ω proteins vary in their antiviral effect, potency, 
or downstream gene induction. Finally, we asked whether IFN-ω proteins induce 
different downstream genes, and whether these differences may vary with known 
parameters like treatment time and IFN dose. Overall, we hypothesized the enhanced 
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flexibility may be associated with an enhanced antiviral defense and potentially also 
disease tolerance. This topic is addressed in Chapter Five. 
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CHAPTER TWO: MATERIALS AND METHODS 
Portions of this chapter are © 2018 Elsevier Inc. and were originally published in 
Pavlovich, et al, “The Egyptian Rousette Genome Reveals Unexpected Features of Bat 
Antiviral Immunity” Cell (2018), DOI: https://doi.org/10.1016/j.cell.2018.03.070. 
Part One: Characterization of the ERB genome 
Source DNA 
The source organism was a wild-caught healthy older juvenile male ERB captured 
at Python Cave in Uganda. Genomic DNA was isolated from the spleen and liver tissue 
by Luke Uebelhoer in the laboratory of Jonathan S. Towner at the Centers for Disease 
Control (CDC) in Atlanta, Georgia using the UltraClean Blood DNA Isolation kit (MO 
BIO Laboratories) with a customized protocol for tissue. Research was conducted under 
an IACUC approved protocol in compliance with the Animal Welfare Act, PHS Policy, 
and other Federal statutes and regulations relating to animals and experiments involving 
animals. 
Library preparation 
Library preparation and sequencing was performed by Galina Koroleva at the 
Center for Genome Sciences at the United States Army Research Institute of Infectious 
Diseases (USAMRIID) in Frederick, Maryland. For sequencing on the Illumina platform, 
1 ug of genomic DNA was sheared to 400 bp using Covaris LE220 Focused-
ultrasonicator (Covaris Inc., Woburn MA). End repair, A-tailing and ligation of adapters 
were performed on the Apollo 324 automated system, using Prep X Complete ILMN 
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DNA Library Kit (WaferGen Biosystems, Fremont, CA). KAPA Library Amplification 
Kit with 10 cycles of PCR was used for library enrichment. Libraries were quantified by 
qPCR using KAPA Library Quantification Kit (KAPA Biosystems, Wilmington, MA). 
Each library was loaded on 8 lanes of the high output flow cell. Cluster amplification was 
performed on the cBot with the TruSeq PE Cluster Kit v3-cBot-HS (Illumina Inc., San 
Diego, CA). Clustered flow cell was sequenced on the HiSeq 2500 instrument. 720 Gb of 
2x101bp paired-end data were produced (approximate coverage of 145x). 
For sequencing on the PacBio platform, genomic DNA was sheared to 20kb 
average size using g-TUBE (Covaris inc.). After DNA damage repair and ends repair, 
hairpin adapters were ligated to form a SMRTbell template. ExoIII and ExoVII treatment 
was used to remove failed ligation products. Size selection was performed on Blue Pippin 
system (Sage Sciences) using 0.75% dye-free agarose gel cassette, marker S1 and Hi-
Pass protocol; low cut was set on 4000 bp. Final library assessment was obtained by 
Qubit dsDNA BR assay and Agilent 2100 Bioanalyzer DNA 12000 chip.  To obtain 
longer reads, libraries were sequenced with P5-C3 chemistry.  Annealing of sequencing 
primer and binding polymerase P5 to the SMRTbell template was performed according to 
PacBio calculator. The polymerase-template complexes were bound to MagBeads, loaded 
onto SMRTcells at final concentration 180 pM, and sequenced with 180 min movies on 
PacBio RS II instrument (Pacific Biosciences, Menlo Park, CA). Approximately 34.9 Gb 
of long-read data (approximate coverage of 24x) were produced, with sizes ranging from 
200-40,991 bases. 
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Genome size estimation 
Genome size estimation was calculated by Sean P. Lovett at the Center for 
Genome Sciences at USAMRIID. K-mers from 4 lanes of the Illumina dataset were 
counted using Jellyfish (Marçais & Kingsford 2011). A peak in 25-mer frequency was 
observed at 57x [Figure 2.1]. Peak k-mer frequency (M), real sequencing depth (N), read 
length (L), k-mer length (K), total bases (T), and genome size (G) are related by the 
following formulas (Li et al. 2010): 
M = N * (L – K + 1) / L 
G = T / N 
 
Figure 2.1 K-mer frequency distribution in Raegyp2.0.  
The percentage (frequency, y-axis) of all 25-mers that are present a given number of 
times (depth, x-axis) in the Rousettus aegyptiacus genome sequence. Figure made by 
Sean P. Lovett. 
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Assembly pipeline 
The assembly pipeline was designed by Stephanie S. Pavlovich and Sean P. 
Lovett, and was executed by Stephanie S. Pavlovich, except for post-processing, which 
was done by Sean P. Lovett. Illumina reads were assembled separately from the PacBio 
reads with SparseAssembler, a short read assembler that exploits high coverage to 
construct a modified de Bruijn graph (DBG) (Ye et al. 2012). Because raw Pacific 
Biosciences (PacBio) long sequencing reads can be error-prone, we corrected potential 
sequencing errors in these reads with ~34x of high-accuracy Illumina reads using 
LoRDEC v0.5 (long read de Bruijn graph error correction) (Salmela & Rivals 2014). 
Contiguity of the short-read assembly was improved by incorporating long-read data 
using DBG2OLC (Ye et al. 2015), which anchors the short-read contigs generated with 
SparseAssembler to the long PacBio reads.  
Multiple approaches were used to scaffold the assembly. First, we used PacBio 
reads with the long-read scaffolding program LINKS v1.5.1, which uses a paired k-mer 
approach to scaffold assemblies with long reads even if they have already been used in 
the assembly (Warren et al. 2015). LINKS was used iteratively until no improvement was 
observed in contiguity, which was after seven iterations. Second, we made use of 
transcriptome data recently published (Lee et al. 2015) to scaffold our assembly with 
L_RNA_Scaffolder (downloaded 9/28/2015) (Xue et al. 2013). Last, we reincorporated 
the paired-end information from our Illumina data for scaffolding with SSPACE v3.0 
(Boetzer et al. 2011). As a post-processing step, we aligned the Illumina reads to the 
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assembly using Bowtie2 (Langmead & Salzberg 2012) and ran the variant calling 
program Pilon (Walker et al. 2014) on the resulting alignment to correct  potential mis-
assemblies, consensus calling errors, or homopolymer indel errors. We also tested the use 
of Quiver (Pacific Biosciences n.d.) as a post-processing step prior to pilon, but found 
that it reintroduced insertion and deletion errors that led to poor gene models (see below). 
The full assembly pipeline is summarized in Illustration 2.1. The Rousettus 
aegyptiacus genome Raegyp2.0 has been deposited in the NCBI GenBank database under 
the accession GCA_001466805.2, and in the RefSeq database under the accession 
GCF_001466805.2. The whole genome shotgun sequencing project accession is 
LOCP00000000.2. 
 
 
Illustration 2.1 De novo assembly pipeline for the Raegyp2.0 genome sequence. 
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Repetitive content and heterozygosity analysis 
Repetitive content and heterozygosity analysis was performed by Sean P. Lovett 
at USAMRIID. Repetitive content was identified based on homology to the RepBase 
database using RepeatMasker (Smit et al. n.d.). “One code to find them all” (Bailly-
Bechet et al. 2014) was used to resolve nested repeats and provide family-level 
quantitative information. All short reads were mapped to the genome using Bowtie2 
(Langmead & Salzberg 2012). Duplicate reads were marked and removed with 
PicardTools v1.131 (Broad Institute n.d.). Variants were called using Samtools v1.3 (Li 
et al. 2009). BCFTools v1.3.1 (Li et al. n.d.) was used to filter variant calls in regions 
with parameters –g3 –G10 –e ‘%QUAL<20 || (RPB<0.1 && %QUAL<30 || (DP<30) || 
(DP>250) || (MQ<20)’.  
Genome annotation 
The assembly was submitted to GenBank (accession GCA_001466805.2) and 
annotated using the NCBI eukaryotic genome annotation pipeline (Thibaud-Nissen et al. 
2013a). A total of 26.25% of the genomic sequence was identified as repetitive by the de 
novo repeat finder WindowMasker (Morgulis et al. 2006) and was masked for the 
purpose of aligning evidence and predicting genes. Transcripts and proteins available in 
GenBank and known RefSeq transcripts and proteins for bats and human were aligned to 
the genome with Splign (Kapustin et al. 2008) and ProSplign, along with model RefSeq 
proteins previously annotated on the Pteropus alecto and Myotis brandtii genomes.  In 
addition, over 2 billion RNA-Seq reads derived from 12 different Rousettus aegyptiacus 
tissues and available in SRA were aligned. Model precursors were created by Gnomon 
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(National Center for Biotechnology Information n.d.), a gene calling algorithm trained on 
Pteropus alecto, by collapsing overlapping alignments with compatible splice patterns. In 
a second step also run by Gnomon, model precursors with high coding propensity were 
extended or joined if missing start or stop codon using an HMM model. The resulting 
models were evaluated and filtered based on multiple criteria, including supporting 
evidence, conflicts with models on the other genomic strand, Blast hits to 
UniProtKB/SwissProt if over 50% ab initio sequence, and number of exons (single-exon 
non-coding RNA were eliminated). Models in the final set were assigned a function by 
orthology calculation to human, or if no ortholog could be calculated, by homology to 
proteins in UniProtKB/SwissProt. Finally, models were assigned GeneIDs and RefSeq 
model transcript and protein accession (with XM_, XP_, XR_ prefixes) and loaded to the 
Nucleotide, Protein and Gene databases as part of NCBI Rousettus aegyptiacus 
Annotation Release 100. 2,198 coding sequences were corrected for premature stop 
codons, small internal gaps, or frameshifts based on aligning evidence (NCBI Eukaryotic 
Annotation Group 2016). When present, the corrected models were used for downstream 
analysis.  
Quality assessment 
To assess the quality of the assembly, we used a statistical analysis program, 
QUAST v3.0 (Gurevich et al. 2013), to look at baseline statistics, including the total 
assembly length, the percentage of estimated genome size covered, and contiguity 
statistics. QUAST v3.0 was also used to generate Nx and NGx plots (see Figure 3.1). To 
check for mis-assemblies, we used the gene coverage program CEGMA v2.5 with 
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mammalian settings to identify the presence and coverage of highly conserved eukaryotic 
genes in the genome (Parra et al. 2007). We also remapped ~54x of short paired reads 
onto the assembly with bwa-mem v0.7.10 and assessed the number of reads that map 
appropriately (in the correct orientation and with the expected insert size) with SAMtools 
flagstat (SAMtools v0.1.18) (Li 2013; Li et al. 2009).  98.41% of reads align, and 91.19% 
of reads map appropriately, indicating no major misassemblies.  
Characterization of gene families 
Homologous protein groups were inferred among 15 species of mammals using a 
similarity-based approach within the OrthoMCL pipeline (Fischer et al. 2011; Li et al. 
2003). The following species were included in the analysis: Rousettus aegyptiacus 
(Egyptian rousette bat), Pteropus vampyrus (large flying fox), Pteropus alecto (black 
flying fox), Myotis davidii, Myotis lucifugus (little brown bat), Homo sapiens, Macaca 
fascicularis (crab-eating macaque), Macaca mulatta (rhesus macaque), Mus musculus 
(mouse), Cavia porcellus (guinea pig), Cricetulus griseus (Chinese hamster), Sus scrofa 
(pig), Bos taurus (cow), Equus caballus (horse), Canis familiaris (dog). Protein data was 
downloaded from RefSeq and filtered to include only the longest protein product of a 
gene for use in the pipeline. Briefly, OrthoMCL gathers all-against-all blastp hits into 
reciprocal best hits (between species) and reciprocal better hits (within species). These 
hits are converted into a graph network describing likely orthologous or paralogous 
relationships among proteins, and MCL clustering is performed to group proteins into 
families. Using OrthoMCL v2.0.9, we obtained 19,310 groups of proteins and 7,041 
single-copy orthologous groups.  
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We annotated all OrthoMCL groups with functional family designations from the 
PANTHER database (Mi et al. 2013; Mi et al. 2016). We first labeled each group with a 
representative RefSeq protein accession from that group, using a protein from a well-
curated genome (human, mouse, macaque) whenever possible. We mapped all RefSeq 
accessions directly to PANTHER family IDs or to UniProtKB accessions for subsequent 
mapping to PANTHER IDs using bioDB, PantherDB, and/or the UniProtKB accession 
mapping feature (Mi et al. 2013; Mi et al. 2016; Mudunuri et al. 2009; Boutet et al. 
2007). All OrthoMCL groups with the same PANTHER family ID were collapsed into 
new gene families, which produced a total of 9,555 gene families (2,400 single-copy 
orthologous gene families). Some families remain unlabeled after this process because 
proteins from relatively new genomes may be missing in PANTHER. Of note, 3,450 
OrthoMCL groups did not map to PANTHER families and were designated unlabeled 
gene families for downstream analysis. Using this process, upon examining the type I 
IFN gene family, we observed that many genes were not accounted for despite being 
present in the NCBI annotation. We discovered that these genes were labeled as 
singletons or in families with only ERB proteins, and therefore would not be classified as 
a PANTHER family since no ERB proteins were in the PANTHER database at the time 
of analysis. We manually corrected the numbers of genes in this family based on NCBI 
annotations and yielding 9,550 families, 3,445 of which were unlabeled. 
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Phylogenetic analysis 
Species Tree 
We extracted all 2,400 single-copy orthologous proteins (inferred by methods 
described above) and performed multiple sequence alignments of each group with Mafft 
v7.305b (Katoh & Standley 2013). All alignments were trimmed with trimAL v1.3 
(Capella-Gutiérrez et al. 2009) using the -automated1 parameter, and concatenated into a 
super-protein for each species. After concatenation, the super-proteins were re-trimmed 
with trimAL (-automated1 parameter) and used to generate a maximum likelihood 
species tree with RAxML v8.2.9 under a JTT + Г substitution model with empirical base 
frequencies (Stamatakis 2014). 1,000 bootstrap replicates were used to assess branch 
reliability. 
Gene phylogenies 
Gene sequences were retrieved from Ensembl release 90 (Yates et al. 2016) by 
looking up the human ortholog (horse ortholog for IFN-δ) and retrieving every annotated 
placental mammal ortholog. To this, we added a curated set of bat orthologs retrieved 
from GenBank. The protein sequences were then aligned in Mega 6.0 (Tamura et al. 
2013) with MUSCLE (Edgar 2004) using a maximum of 20 iterations. Mega 6.0 was then 
used to estimate the most likely model, which in all cases was JTT+Γ (Jones et al. 1992). 
This model was used to generate phylogenies for each gene. Sites were not considered for 
phylogenetic analysis if a deletion was present in >5% of sequences (10% for NKG2A). 
Bootstrap confidence values were determined using 500 replicates. This analysis was 
performed by Sean P. Lovett at USAMRIID. 
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Gene family evolution 
Gene families from the proteomes of 15 mammals (as designated in above 
methods) were used as input for the CAFE v3.1 (Computational Analysis of gene Family 
Evolution) algorithm (De Bie et al. 2006) to estimate a value for lambda (the birth and 
death rate for a given gene per million years) by maximum likelihood. Since CAFE 
assumes that all input gene families have at least one member in the most recent common 
ancestor of all species, gene families were filtered to exclude single lineage families. To 
make sure families were present in the most recent common ancestor of all studies 
species, only families with at least one gene in both the Laurasiatheria superorder (bats, 
ungulates, carnivores) and the Euarchontoglires superorder (primates, rodents) were 
included. The resulting families were further filtered to exclude eight families with large 
ranges in size (>100) across the tree, leaving 7,698 families for expansion and contraction 
analysis. CAFE was used to obtain a maximum likelihood estimate of a global birth and 
death rate parameter λ (lambda; rate of gain/loss per gene per million years) across the 
species tree (created by above methods) of 0.0169284. The size of each family at each 
ancestral node was estimated and used to obtain a family-wise p-value to indicate non-
random expansion or contraction for each family, as well as significant expansion or 
contraction across all branches of the species tree.  
Selection analysis 
Among many others, we included genes involved in dendritic cell maturation, 
induction and signaling of type I IFNs, and cytokine responses, since dysfunctions of 
these pathways have all been reported as contributors to the pathogenesis of MARV in 
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primates (Caballero et al. 2014; Connor et al. 2015; Brauburger et al. 2012). We also 
included genes in DNA damage response pathways, since adaptations in DNA damage 
responses during the selection for flight in bats have been hypothesized to influence 
immune responses in bats (for a full list of genes studied, see Table S5 in Pavlovich et al. 
2018). All genes of interest (immune genes, echolocation genes, flight genes) were 
downloaded from RefSeq in Genbank format and coding sequences for each gene were 
extracted using a python script. For each member of an ortholog group, the longest 
isoform was selected. Amino acid sequences of ortholog groups were aligned with 
Muscle v3.8.31 (Edgar 2004). The resulting alignments were then trimmed with trimAl 
v1.4 (Capella-Gutiérrez et al. 2009) to retain only high-quality aligned regions and 
alignment columns containing gaps. We used codeml within the PAML v4.9b suite of 
phylogenetic analysis tools to estimate ω, the nonsynonymous/synonymous nucleotide 
substitution rate ratio, and κ, the transition/transversion rate ratio with the F3 x 4 codon 
frequency matrix (Bielawski & Yang 2005; Yang 1998). Seven separate models were 
used [Illustration 2.2] and maximum likelihood scores estimated for each. Likelihood 
ratio tests were performed, progressively allowing more degrees of freedom. Two-ratio 
unconstrained models were first tested against the one-ratio null model to test for 
differential selective pressure. Any gene for which the null model was rejected proceeded 
to testing of the most likely two-ratio model against all three-ratio models in which it was 
nested using the same procedure, and, finally, any gene for which the two-ratio model 
was rejected against any three-ratio model proceeded to testing the most likely three-ratio 
model against the four-ratio model. FDR was controlled at each level using the 
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Benjamini-Hochberg procedure (Benjamini & Hochberg 1995). Models showing ω1 > 1 
along any branch were then compared against two-ratio constrained models with ω1 fixed 
at 1 to test for neutral evolution. Branches showing significantly higher than average, but 
not greater than 1, ω1 may have positively selected sites. However, relaxation of 
purifying selection along these branches cannot be ruled out using these models. 
Analyses were run with multiple starting values of both κ (2,2.5,4) and ω (0.1,1,2) to 
provide a check against local optima. These analyses were automated using LMAP v1.0.0 
(Maldonado et al. 2016). The analysis and models were designed by Thomas B. Kepler 
and Stephanie S. Pavlovich at BUSM, and Sean P. Lovett at USAMRIID. The analysis 
was carried out by Sean P. Lovett. The genes that were found to have evidence of relaxed 
purifying selection or positive selection pressures were mapped onto pathways in 
Ingenuity Pathway Analysis (IPA; QIAGEN 
Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis). See 
Figure S3.1 
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Illustration 2.2. Model selection hierarchy for positive and purifying selection 
analysis 
RA = R. aegyptiacus, Mega = megabats other than R. aegyptiacus, Micro = microbats, 
Non-bat = all species in non-bat branches (human, crab-eating macaque, rhesus macaque, 
mouse, dog, cow, pig, guinea pig, hamster, and horse). Arrows indicate nested models 
(e.g., an arrow pointing from Model 1a to 2a means that Model 1a is nested in Model 2a). 
For each applicable model, color indicates which branches were used to estimate which 
evolution rate (orange - ω1; green - ω2; purple - ω3; grey - ω0, i.e. the background rate of 
evolution). Model 0 was the best-fitting for 330 genes, Model 1a for 5 genes, Model 1b 
for 65 genes, Model 1c for 23 genes, Model 2a for 0 genes, model 2b for 32 genes, and 
Model 3 for 1 gene. 
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Gene annotation 
We used annotations derived from the NCBI pipeline to extract and characterize 
NK cell receptor genes and MHC genes. These annotations were supplemented with 
homology-based predictions from the gene family analysis described above, and manual 
correction after examination in BioEdit v7.0.0 (Hall 1999). For example, out of the 12 
genes classified as C-type lectins in our gene family analysis, one gene is missing exons 
and is considered a pseudogene. The NCBI gene database contains another gene 
annotated as an NKG2A-like gene, but was classified as a singleton in our gene family 
analysis because of missing exons. Additionally, one protein sequence identified as an 
NK cell receptor-like C-type lectin by our gene family analysis remained uncharacterized 
by the NCBI pipeline. Upon manual reannotation, we discovered that the uncharacterized 
protein sequence was actually a misannotation of two NKG2A-like genes—one complete 
pseudogene and one partial gene. Thus, this analysis is able to detect homologs and is 
robust to potential misannotation issues. To annotate the type I IFN genes, we used IFN 
sequences inferred from P. vampyrus sequencing traces from Kepler et al. 2010 as 
queries in a blastn search with the following parameters: -task blastn -evalue 0.05. 
Resulting hits were screened based on the lowest e-value, and the sequences were 
extracted with blastdbcmd and examined in BioEdit v7.0.0 for coding potential (Altschul 
et al. 1990; Hall 1999). To extract MHC class I putative nonamers, proteins derived from 
MHC class I genes (or the closest mouse homologs to HLA-A) were aligned, and 
nonamers determined based on location of known nonamer sequences (O’Callaghan 
2000; Kaiser et al. 2008). NKG2D ligands were collected from the NCBI Gene database 
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or from UNIPROT (Boutet et al. 2007; Bateman et al. 2015). For bat proteins, all putative 
functional, in-frame, non-partial genes were identified based on their annotation as 
NKG2D ligand-like by the NCBI Eukaryotic Annotation pipeline. 
Transcriptome analysis 
Transcriptome analysis was performed by Sean P. Lovett at USAMRIID. Reads 
from the Lee, et al 2015 dataset (SRA project: SRP066106) (Lee et al. 2015) were 
pseudoaligned to the set of CDSs annotated in the Raegyp_2.0 assembly supplemented 
with manually annotated type I IFN genes and NKG2 genes using kallisto v0.43.0 (Bray 
et al. 2016). Gene-level transcript counts were calculated by summing the transcript per 
million (TPM) values for all transcripts of a given gene. The resulting TPM values were 
log2 transformed and heatmaps were generated using pheatmap (Kolde 2012). For Table 
S4.1, TPM values of IFNs were normalized by dividing by GAPDH TPM in the same 
tissue. 
 
Sendai virus interferon induction study 
Sendai virus infection of RoNi cells 
This experiment was performed by Jonathan C. Guito at the CDC. RoNi cells 
were seeded at 5x104 in 24-well plates (Corning), then infected in triplicate by Sendai 
virus (SeV, Cantell strain, Charles River Laboratories, Wilmington, MA) at an MOI of 1, 
or mock infected. Fresh media was exchanged following a 1hr adsorption and plates were 
incubated at 37°C. Cells were harvested in 1x RNA Lysis/Binding Solution Concentrate 
(Thermo Fisher Scientific, Waltham, MA) at 3hr, 8hr and 24hr post-infection, followed 
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by magnetic bead purification and TURBO DNase treatment using the MagMAX-96 
Total RNA Isolation Kit (Ambion, Thermo Fisher Scientific) according to manufacturer 
guidelines. RNA extractions were performed by Ayan K. Chakrabarti at the CDC on a 
MagMAX Express 96 Magnetic Particle Processor (Applied Biosystems). Purified total 
RNA samples were verified by NanoDrop spectrophotometer (Thermo Fisher Scientific) 
and stored at -80°C prior to use. 
Library preparation and sequencing 
RNA library preparation and sequencing was performed by Elyse R. Nagle at 
USAMRIID. RNA libraries were generated using the TruSeq Stranded Total RNA 
Library Prep Kit with Ribo-Zero Human/Mouse/Rat High-Throughput kit (Illumina, 
Inc.). The completed libraries were screened for quality with the High Sensitivity D1000 
Screentape and Reagents on the Tapestation 2200 (Agilent) and the Library 
Qauntification kit (KAPA Biosystems). RNA-sequencing was performed using a dual-
index paired end (2x125 bp) format on Illumina HiSeq 2500 with the Hiseq SBS Kit v4 
(250 cycles) and the HiSeq PE Cluster Kit v4 (Illumina, Inc.). 
Data analysis 
Data were analyzed and plotted by Catherine E. Arnold at USAMRIID. Raw 
reads were cleaned with Trimmomatic v0.33 (Bolger et al. 2014), aligned to the ERB 
transcriptome (from NCBI, supplemented with manually annotated type I IFN genes and 
NKG2 genes) and quantified in TPM using kallisto v0.43.0 as described in the 
transcriptome analysis section (Bray et al. 2016). 
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Part Two: Characterization of ERB interferon-ω proteins 
Phylogenetic and sequence analysis 
IFN-ω genes were annotated as described above and examined in BioEdit v7.0.0 
(Hall 1999). Genes were translated into protein sequences within BioEdit. Sequences 
were aligned with Mafft v7.305b (Katoh & Standley 2013) (-auto parameter), and the 
resulting alignment was trimmed with trimAL v1.3 ( -automated1 parameter) (Capella-
Gutiérrez et al. 2009). The trimmed alignments were used to generate maximum 
likelihood phylogenetic trees with RAxML v8.2.9 under a JTT + Г substitution model 
with empirical base frequencies (Stamatakis 2014). 100 bootstrap replicates were used to 
assess branch reliability. The best scoring maximum likelihood tree was analyzed in 
MEGA v7.0.26 (Kumar et al. 2016). 
To capture as many possible receptor binding sites, each protein was used as input 
into the NCBI conserved domain database search 
(https://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) (Marchler-Bauer et al. 2017; 
Marchler-Bauer et al. 2015), which relies on previous published work to pick out possible 
IFNAR1 and IFNAR2 binding sites (Radhakrishnan et al. 1999; Karpusas et al. 1997; 
Klaus et al. 1997). The residues at each site (20 sites for IFNAR1 and 27 for IFNAR2) 
were compared across all ERB IFN-ω proteins (every protein compared to every other 
protein), and the total number of conserved sites divided by the total number of sites (47) 
is reported in Table 5.1 for each clade.  
Protein sequences were also used as input for signal sequence prediction via the 
Signal P v4.1 server (http://www.cbs.dtu.dk/services/SignalP/) (Petersen et al. 2011). 
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Proteins were then aligned to the human IFN-ω with ClustalW within BioEdit and the 
predicted signal peptides (amino acids 1-21) were cleaved. The proteins were then 
compared to human IFN-ω and important binding sites from Thomas et al. 2011 were 
labeled (See Figure 5.2). 
Cell lines 
Rousettus aegyptiacus immortalized fibroblasts (RoNi) were originally generated 
in the work described in Biesold et al. 2011. Cells were cultured at 37°C at 5% CO2 in 
DMEM (Dulbecco’s Modified Eagles Medium) with 4.5 g L glucose supplemented with 
10% fetal bovine serum, 100 U per mL penicillin, 100 μg/mL streptomycin, 2 mM L-
Glutamine, 1 mM Sodium Pyruvate, and 100 μM MEM nonessential amino acids 
(Lonza).  
Egyptian rousette primary fibroblasts were cultured from wing punches from a 
male ERB from the Lubee Bat Conservancy (Gainsville, Florida.) by Whitney Manhart at 
BUSM. The biopsy was shredded using a sterile scalpel and plated in a 10 cm dish with a 
digestion solution (6:1 DMEM with 20% FBS to collagenase) and incubated for 24 hours 
at 37°. The biopsy was then transferred into a conical tube and centrifuged at 300 rcf for 
10 minutes. After washing the pellet twice with PBS, the cell pellet was resuspended in 2 
mL of complete medium (DMEM, 10% FBS, 2 mM L-glutamine, 1 μg/mL Primocin™ 
(Invitrogen)) and plated in a gelatin-coated 6 well plate. Adherent cells expanded and 
were passaged again. Cells from each subsequent passage were plated on a gelatin-coated 
plate in ERB medium (DMEM, 10% FBS, 2 mM L-glutamine, 100 μM Non-essential 
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amino acids, 1 μg/mL Primocin™ (Invitrogen).) Cells were maintained for up to 6 
passages.  
Human FreeStyle 293F cells (ThermoFisher Scientific) were maintained in 
FreeStyle™ 293 Expression Medium (ThermoFisher Scientific) at 37°C at 8% CO2 with 
continuous shaking at 135 rpm. All work with live 293F cells was conducted without 
direct light because of the light-sensitivity of the medium. 
Protein expression in 293F cells 
293F cells at a density of 1x106 cells per mL in a volume of 30 mL were 
transfected with plasmids encoding pCAGGS/6xHis–IFN-β1, –IFN-ω1, –IFN-ω3, –IFN-
ω4, –IFN-ω9, and –IFN-ω12 (Blue Heron Biotech, Bothell WA) using FreeStyle™ MAX 
reagent diluted in OptiPRO™ SFM (ThermoFisher Scientific) according to the 
manufacturer’s protocol 
(https://www.thermofisher.com/us/en/home/references/protocols/cell-
culture/transfection-protocol/freestyle-max-reagent.html#2). 3 days post-transfection (or 
when viability was below 70% as determined by 0.1% erythrocin B staining), clarified 
supernatant (centrifuged at 4°C for 1 hour at 4000 rpm) was collected and frozen at -20°C 
till purification. BL21(DE) cells were transformed with pET22b/6xHis-PA-D1 and 
streaked on LB agar plates containing 50 µg/mL ampicillin. Resulting colonies were 
grown in 4 mL of 2x Yt medium containing 50 µg /mL of ampicillin at 37°C till a 600 
nm OD of 0.6 was reached. 3 mL of starter culture was added to 97 mL of 2x Yt medium 
(ampicillin 50 µg/mL) and grown till a 600 nm OD >1. Cells were stimulated with IPTG 
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(0.5 mM) for 3 hours at 37°C, and then spun down. Cell pellets were frozen at -20°C 
before protein purification.  
Purification of recombinant proteins 
Proteins were purified via a Capturem His-tagged purification maxiprep kit 
(Clontech, Takara Bio), eluted in 1.5 mL of elution buffer (containing 500 mM 
imidazole) from the kit, and dialyzed into sterile 1x PBS using a Vivaspin 2 protein 
concentration column (MWCO 10kDa; GE Life Sciences). 
Characterization of purified proteins 
Proteins were quantified by 280 nm absorbance measured on a NanoDrop 
spectrophotometer and Bradford assay (Biorad, Hercules, CA). Proteins were 
characterized by SDS-PAGE, followed by Western blot analysis using an anti-His-tag 
antibody or silver staining. Briefly, proteins were diluted in 1x PBS and 6x sample buffer 
(250mM Tris-HCl (pH 6.8), 10% SDS, 30% Glycerol, 5% β-mercapitalethanol, 0.02% 
bromophenol blue). Diluted samples were boiled at 100°C for 8 minutes, cooled on ice, 
and run on a 4%-20% gradient SDS-PAGE gel (Mini-PROTEAN® TGX™ Precast Gels, 
Biorad) at 75 volts in electrode buffer. Gels were either prepared for protein 
quantification by Western blot analysis using an anti-His-tag antibody (primary antibody 
– 1:1000 anti-6x-His tag mouse mAb, Thermo Fisher #MA1-21315; secondary antibody 
– 1:3000 Amersham ECL sheep anti-mouse IgG, HRP-linked, GE Life Science #NA931), 
or silver staining using the Pierce Silver Stain assay kit (Thermo Fisher) according to the 
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manufacturer’s protocol. Proteins were stored at -20°C. Immediately before use, proteins 
were diluted in 1x PBS and sterile filtered with a 0.2 μm pore filter. 
Antiviral assay 
RoNi or primary ERB fibroblast cells in medium supplemented with 10% FBS 
were seeded at a density of 3x104 cells per well in 96-well plates, and treated with serial 
dilutions of recombinant 6xHis-tagged IFN-β1 (rIFN-β1), recombinant 6xHis-tagged 
IFN-ω3, -ω4, -ω9, -ω12, Universal IFN (UIFN, PBL Assay Science, Piscataway, NJ), or 
an unrelated recombinant 6xHis-tagged protein (rPA-D1) for 4, 6, or 8 hours at 37°C. 
The interferon-containing media were removed, and cells were infected with VSV 
encoding eGFP (VSV-eGFP; kindly provided by John Connor, Boston University School 
of Medicine) at an MOI of 0.05 in medium supplemented with 2% FBS, and imaged for 
GFP expression 1 day post infection (multiple viral life cycles). 
Interferon-ω RNA-Seq study 
Interferon treatment 
RoNi cells were seeded at a density of 2.5x105 cells per well in 12-well plates, 
and treated with 1000 U of UIFN, medium alone, or dilutions of rIFN-ω4, rIFN-ω9, or 
rPA-D1 (0.01 ng/mL, 1 ng/mL, or 100 ng/mL) for 4 or 8 hours at 37°C. Medium was 
removed and 600 μL of RNAzol RT (Molecular Research Center Inc #RN 190, 
Cincinnati, OH) was added to each well. RNA in RNAzol was then transferred to an 
RNAse-free tube, vortexed for 20 seconds, and immediately stored at -80°C. Experiments 
were performed in triplicate, resulting in a total of 66 samples. 
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RNA extraction, library preparation, and sequencing 
RNA was extracted using a previously established protocol for RNAzol. Briefly, 
240 µL of nuclease-free water (0.4x RNAzol volume, Ambion #AM9937) was added to 
each sample, followed by vigorous vortexing and pelleting of DNA and protein 
components. RNA was precipitated with isopropanol (equal volume) and 20 µg of 
glycogen (stock of 20 µg/µL, Invitrogen #10814-010), and washed twice with 75% 
ethanol, before resuspension in nuclease-free water. RNA was quantified by Nanodrop 
and a subset of samples was assessed for quality by BioAnalyzer (Agilent) evaluation on 
an RNA chip. All samples tested had RIN scores of 10.  
1.25 µg of RNA was used as input for the TruSeq® Stranded mRNA Library Prep 
kit (Illumina). Briefly, mRNA was purified by polyA capture and fragmented to an 
average length of approximately 410 bp. The first strand of cDNA was synthesized with 
SuperScript II Reverse Transcriptase (Thermo Fisher #18064014), followed by second 
strand synthesis and cleanup with AMPure XP beads (Beckman Coulter #A63880). The 
resulting double-stranded cDNA was stored at -80°C until 3’ adenylation and end repair 
the following day. Samples were barcoded with adapters from the TruSeq RNA CD 
Index Plate (Illumina), cleaned with AMPure XP beads, and libraries were enriched by 
PCR for 12 cycles. Final libraries were washed twice with AMPureXP beads (final bead 
wash ratio: 0.85x to remove adapter dimers), and quantified by Qubit 3.0 assay. A subset 
of samples was examined by DNA Bioanalyzer (Agilent) for quality purposes before 
pooling samples within each of three replicates. Pooled libraries were sent to Tufts 
Genomics Center for size selection (pippin size selection, 180 bp – 1100 bp) and 
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sequencing. Each library was sequenced on a separate lane of an eight-lane flow cell in 
high output mode on an Illumina HiSeq 2500 using single-end 100 bp chemistry.  
RNA-Seq differential expression analysis 
Raw reads were demultiplexed by the Tufts Genomics Center and evaluated for 
quality with FastQC v0.11.3. Remaining 5’ adapter sequences were trimmed using 
cutadapt v1.5, and all reads shorter than 50 bp were discarded. Trimmed reads were 
mapped to the Raegyp2.0 genome (RefSeq accession: GCF_001466805.2) with hisat2 
v2.1.0, with an average mapping rate of 97.1%. Count tables of uniquely mapped reads 
were tabulated with HTSeq v0.6.1p1 (Anders et al. 2015)with the parameters --
stranded=reverse and --mode=union for htseq-count with a gtf annotation file from 
RefSeq (with modifications to use GeneID as the ID attribute). Count tables were used 
for pairwise differential expression analysis (and multiple hypothesis testing correction) 
with edgeR (Robinson et al. 2010; McCarthy et al. 2012) within the R environment (R 
version 3.4.3). First, an ANOVA-like test was performed where each treatment (D1, IFN-
ω4, IFN-ω9) was compared to all other treatments for a given treatment concentration 
and time. For all genes rejecting the null in the ANOVA-like test with an FDR less than 
or equal to 0.05 (Benjamini-Hochberg procedure), each IFN-treated sample was 
compared to the corresponding D1-treated sample at the same concentration and time 
point (e.g., treatment with 1 ng/mL of IFN-ω4 for 4 hours compared to treatment with 1 
ng/mL of rPA-D1 for 4 hours), and IFN-ω4 was compared to IFN-ω9 for the same 
conditions. Genes were considered differentially expressed if the p-value of the pairwise 
comparison was less than 0.05/3 and if the absolute value of the log2 fold change in the 
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pairwise comparison was greater than 1. UIFN-treated samples were compared to 
untreated samples at the same time point, with an FDR < 0.05 and the absolute value of 
the log2 fold change was greater than 1. Gene symbols were mapped back onto Gene IDs 
with the rentrez package in R. Plots were generated in R with the pheatmap (Kolde 2012) 
and ggplot2 packages, except for Venn diagrams, which were produced in Venn diagram 
plotter (v1.5.5228.29250). 
Quantification and statistical analysis 
Significance of expanded and contracted gene families was determined as 
follows: CAFE v3.1 provides a family-wide p-value for gene families that evolved 
differently than expected, and additionally provides a Viterbi p-value that assigns a p-
value to the contribution of each species to the family-wide evolution across the tree (De 
Bie et al. 2006). The Benjamini-Hochberg procedure was applied to family-wide p-values 
for the gene families that evolved differently than expected. The p-values were ranked 
from lowest to highest with identical p-values assigned the same rank, and the rank for 
the next non-identical p-value incremented by the total size of the identical group. The 
rank of each p-value was divided by the total number of hypotheses (7,698, for each gene 
family) and multiplied by 0.05 to obtain the adjusted p-value with a false-discovery rate 
of 0.05. For families with adjusted p-values < 0.05, the Viterbi p-values were used to 
determine whether the expansion or contraction in a specific lineage was significant. 
Families with expansions and contractions in Figure 3.2 have family-wide adjusted p-
values less than 0.05 and Viterbi p-values less than 0.05.  
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Significance of differential expression between Sendai virus-infected samples and 
mock-infected samples in Figure 4.16 was determined via an unpaired two tailed t-test 
with TPM values from three biological replicates, with adjusted p-values considered 
significant if less than 0.05. 
Meta-analysis of viremia and oral shedding of MARV-infected Egyptian rousette 
bats from two previous studies (Amman et al. 2015, Schuh et al. 2017b) in Figure 1.1 was 
done by Jonathan C. Guito at the CDC. Meta-analysis was conducted by averaging raw 
TCID50 equivalent units per mL values across both experiments, with values matched to 
respective time point post-infection up to 28 days. The standard deviation of the averages 
was taken for each time point against the number of MARV-positive bat samples, except 
at time points with fewer than two MARV-positive bats. Linear values were then 
converted into log form, and trendlines of the average log values from each dataset across 
time were included using the moving average option with a periodicity of 2. 
 
Supplemental material 
Primer sequences 
pCAGGS primers were ordered from Integrated DNA Technologies, (IDT; Coralville, 
IA) as standard desalted lyophilized oligos. pET22b contains a T7 RNA polymerase 
promoter and primers binding to the T7 RNA polymerase promoter were used directly 
from Genewiz. All primers are shown in 5’ to 3’ direction.  
Table S2.1 Primers for Sanger sequencing of pCAGGS plasmids 
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Target Forward Reverse 
pCAGGS CCT TCT TCT TTT TCC TAC AG CCT TTA TTA GCC AGA AGT CAG 
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CHAPTER THREE: THE EGYPTIAN ROUSETTE BAT GENOME IS A 
USEFUL TOOL FOR STUDYING BAT IMMUNOLOGY 
Portions of this chapter are © 2018 Elsevier Inc. and were originally published in 
Pavlovich, et al, “The Egyptian Rousette Genome Reveals Unexpected Features of Bat 
Antiviral Immunity” Cell (2018), DOI: https://doi.org/10.1016/j.cell.2018.03.070. 
 
Rationale 
Examining genetic and genomic information in bats is useful for generating both 
hypotheses and experimental tools for studying bat immunology. Multiple bat genomes 
are now available, but while they provide important insights into the unique biology of 
bats, they were generated with low-coverage sequencing, or with only short-read next-
generation sequencing (NGS) technologies (Zhang et al. 2013; Seim et al. 2013). These 
sequencing strategies impact the overall contiguity of genome assemblies, and severely 
limit the ability to resolve repetitive genome loci where important immune gene loci 
reside.  
The Egyptian rousette, also known as the Egyptian fruit bat (ERB; species: 
Rousettus aegyptiacus), is a reservoir for all known marburgviruses, which are filoviruses 
that can cause severe systemic disease with a high case-fatality rate in primates (Towner 
et al. 2009). MARV-infected bats show transient viremia with no overt pathology (Jones 
et al. 2015, Amman et al. 2015). Until now, detailed study of the adaptations that allow 
the ERB to immunologically control MARV has been impeded by the lack of an ERB 
reference genome. To fill this knowledge gap, and to overcome the contiguity limitations 
of previous bat genome projects, we sequenced and annotated the ERB genome using a 
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hybrid strategy of short (Illumina HiSeq 2500) and long (Pacific Biosciences RS II) 
reads. Here, we use this genome, the most contiguous bat genome available, to 
understand the evolution of immune genes and gene families in bats, and describe several 
observations relevant to defense against viruses. 
 
Results 
3.1 A hybrid assembly approach results in a high-quality, contiguous genome. 
Genomic DNA was isolated from the spleen tissue of a healthy older juvenile 
male Rousettus aegyptiacus bat captured at Python Cave in Uganda and sequenced to 
high coverage using two platforms, the Illumina HiSeq 2500 and the Pacific Biosciences 
(PacBio) RS II, obtaining 100 bp short reads and up to nearly 41,000 bp long reads, 
respectively. We produced 720 Gb of paired-end short-read data (approximate coverage 
of 145x) and 34.9 Gb of long-read data (approximate coverage of 24x).  
Megabat genomes are known to be significantly smaller than those of other mammals 
(Smith & Gregory 2009). The size of the ERB genome was previously estimated to be 
2.11 Gb, with a 2n chromosome number of 36 (Kwiecinski & Griffiths 1999; Smith & 
Gregory 2009). To validate this estimate, we calculated genome size using the k-mer 
analysis method with a subset of our Illumina dataset, and estimate a complete genome 
size of 2.08 Gb, which is very close to the previous approximation by Smith and Gregory. 
After hybrid assembly of short-read contigs and error-corrected long-reads, and 
subsequent scaffolding and post-processing, we generated a highly contiguous draft 
genome (Raegyp2.0) comprising 1.91 Gb of sequence represented in 2,490 scaffolds 
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(N50 = 2.007 Mb; NG50 = 1.811 Mb), which is roughly 90% of the estimated genome 
size. The genome-wide average GC content is about 40%, and intra-scaffold GC content 
ranges from 31.1% to 71.4%. The ERB genome shows a higher degree of heterozygosity 
(0.53%, Table 3.1) than has been reported for other bat genomes (Zhang et al. 2013). The 
genome size and N50 are comparable to the assembled genomes of other bats; however, 
Raegyp2.0 has a larger contig N50 and a lower total gap length than any other available 
bat genome, making it the most contiguous bat genome to date [Table 3.2]. This finding 
is supported by closeness of the Nx scaffold and contig curves [Figure 3.1]. 
To determine the quality of the draft genome, we mapped a subset of input 
Illumina paired-end reads (~54x) onto Raegyp2.0 and found that 98.41% of reads align, 
and 91.19% of reads map appropriately (in the correct orientation and with an insert size 
in the expected range). In addition, we used the gene coverage program CEGMA to 
identify the presence and coverage of highly conserved eukaryotic genes in Raegyp2.0 
(Parra et al. 2007). Of 248 core eukaryotic genes, 88.31% were complete in the genome, 
while 92.34% were at least partially represented, suggesting that gene information is 
covered well. Raegyp2.0 was also used in an independent study; core eukaryotic genes 
evaluated by another gene coverage program (BUSCO, Simão et al. 2015) were found to 
be 98% complete with 1% fragmented, 1.60% duplicated, and 0.50% missing 
(Tsagkogeorga et al. 2017).  
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 SNPs  Indels  
 
Number of 
sites 
Percent of 
genome 
 Number 
of sites 
Percent of 
genome 
Total percent 
of genome 
R. aegyptiacus 10,065,960 0.527  1,002,056 0.052 0.579 
P. alecto 8,790,573 0.453  1,312,432 0.068 0.521 
M. davidii 5,140,505 0.279  956,196 0.052 0.331 
M. brandtii 7,312,602 0.371  1,271,833 0.065 0.436 
Table 3.1 Heterozygosity of Raegyp2.0.  
The number of single-nucleotide polymorphisms (SNPs) and insertions or deletions 
(indels) site in multiple bat genomes, and their percentage of the total genome. See 
“Repetitive content and heterozygosity analysis” in Chapter Two. 
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Species 
(Assembly 
Name) 
Scaffold 
N50 
(Kb) 
Contig 
N50 
(Kb) 
Total 
length 
(Gb) 
Total gap 
length 
(Mb) 
Coverage/Sequencing 
Technology 
Rousettus 
aegyptiacus 
(Raegyp2.0) 
2,007.2 1,489.0 1.910 0.482 
169.2x Illumina HiSeq 
2500 and Pacific 
Biosciences RS IIa 
Pteropus 
vampyrus 
(Pvam_2.0) 
5,954.0 21.9 2.198 181.040 188.0x Illumina 
Pteropus alecto 
(ASM32557v1) 
15,954.8 31.8 1.986 41.334 
110x Illumina HiSeq 
2000 
Myotis lucifugus 
(Myoluc2.0) 
4,293.3 64.3 2.035 68.155 7x Sanger 
Myotis brandtii 
(ASM32734v1) 
3,225.8 23.3 2.107 125.473 
120x Illumina HiSeq 
2000 
Myotis davidii 
(ASM32734v1) 
3,454.5 15.2 2.060 181.338 
110x Illumina HiSeq 
2000 
Miniopterus 
natalensis 
(Mnat.v1) 
4,315.2 29.8 1.803 68.170 77.0x Illumina HiSeq 
Eptesicus fuscus 
(EptFus1.0) 
13,455.9 21.4 2.027 215.248 84x Illumina HiSeq 
Megaderma lyra 
(ASM46534v1) 
16.9 7.0 1.736 20.607 18.0x Illumina HiSeq 
Eidolon helvum 
(ASM46528v1) 
27.7 12.7 1.838 7.320 18.0x Illumina HiSeq 
Rhinolophus 
ferrumequinum 
(ASM46549v1) 
21.2 11.7 1.926 4.731 17.0x Illumina HiSeq 
Rhinolophus 
sinicus 
(ASM188883v1) 
3,754.4 37.8 2.073 58.015 
146.44x Illumina 
HiSeq 
Pteronotus 
parnellii 
(ASM46540v1) 
22.7 9.5 1.960 13.7 17.0x Illumina HiSeq 
Hipposideros 
armiger 
(ASM189008v1) 
2,328.2 39.9 2.237 281.734 218.6x Illumina HiSeq 
Table 3.2. Sequencing strategy, coverage, and contiguity statistics of available bat 
genomes.  
  
56
The contiguity statistics (scaffold and contig N50, total length, and total gap length) are 
reported for each bat genome available in the NCBI GenBank database (accessed on 
8/8/17), along with the GenBank Assembly Name and the given coverage. Kb, Mb, Gb: 
kilobases, megabases, gigabases. a Roughly 145x coverage of Illumina HiSeq 2500 data 
and 24x coverage of Pacific Biosciences RS II data. 
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Figure 3.1. Scaffold and contig Nx and NGx plots for Raegyp2.0 
A. Nx and B. NGx plots in megabases (Mbp) for Raegyp2.0 with an estimated reference 
genome size of 2.11 Gb. These plots (generated using QUAST) show the shortest 
sequence for which the total length of all sequences of its length or longer make up “x” 
percentage of the total assembly size (Nx) or the total estimated reference genome size 
(NGx). For example, in a length-sorted list of sequences, the N50 refers to the length of 
the smallest sequence for which the sum of the length of all sequences of the same or 
longer length constitute 50% of the total assembly length. The scaffold N50 refers to the 
N50 of all the scaffolds in the genome, while the contig N50 refers to the N50 of all the 
contigs in the genome.  
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3.2 Post-assembly processing with Quiver reintroduces indels because of poor allelic 
recognition 
Given that we used relatively low coverage of Illumina reads to remove erroneous 
insertions and deletions in the PacBio data, we performed post-assembly filtering 
correction with the Quiver and pilon algorithms to make sure that all remaining insertion 
and deletion errors were eliminated prior to annotation. Quiver is a variant-calling 
algorithm that performs quality value-informed alignment of PacBio reads to a draft 
genome and outputs a consensus sequence based on the read information. It is 
recommended for assemblies using PacBio data as a polishing step to maximize the 
accuracy of the consensus sequence (Chin et al. 2013; Chakraborty et al. 2015). Pilon is a 
variant-calling and assembly improvement algorithm that uses high-quality short-read 
data like Illumina paired-end reads to identify and fix incorrect base calls, gaps, and 
misassemblies in draft genomes (Walker et al. 2014).  
When both Quiver and pilon were used as in post-processing step, the NCBI 
annotation pipeline (see Genome Annotation) predicted roughly 19,300 gene models in 
the draft genome. This is similar to the number of genes in other mammals, indicating 
that the genome does not have major misassemblies [See Table 3.3] in the coding regions 
and that it covers a significant amount of the putative coding regions. However, more 
than half of the predicted genes (~10,000), had erroneous insertions and deletions that 
frame-shifted coding sequences and resulted in their being annotated as pseudogenes. We 
used intermediate output from the NCBI eukaryotic annotation pipeline to determine 
where the errors had arisen, and found that eliminating Quiver from the pipeline resulted 
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in the correction of 95% of the erroneous insertions and deletions in coding regions. 
Eliminating Quiver also reduced the predicted number of pseudogenes from 10,953 to 
2,053, which is similar to that in other bats [see Table 3.3].  
To date, Quiver has mainly been used as a polishing step for microbial genome 
projects, and has produced impressive improvements in Phred quality values in PacBio-
only assemblies (Chin et al. 2013). It has also been used with success in larger genomes, 
like Drosophila melanogaster and a human haploid hydatidiform mole cell line (CHM1) 
(Berlin et al. 2015). However, these reference genomes had the benefit of little to no 
heterozygosity in the sequencing data. Genome projects dedicated to more heterozygous 
genomes report increases in insertion errors despite using Quiver. In both the long-read-
based human and gorilla genome projects, the authors observed an excess of single-base 
insertions and subsequently corrected them with Illumina data to produce the final high-
quality assemblies (Gordon et al. 2016; Pendleton et al. 2015). In the ERB genome, 
which is considerably heterozygous, we find a similar excess of single-base insertions 
after using Quiver. Our results suggest that Quiver can introduce insertion and deletion 
errors in more heterozygous mammalian genomes because it does not accommodate 
alleles well. This can lead to subsequent issues with genome annotateability. 
 
3.3 A large number of genes are well-annotated in Raegyp2.0 
Whole-genome annotation was performed via the NCBI eukaryotic annotation 
pipeline with inputs of the draft genome assembly and all ERB-specific transcript and 
RNA-Seq data in the NCBI databases, as well as proteins of other well-characterized 
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species (Thibaud-Nissen et al. 2013b). The genome contains 36.4% repetitive content, 
similar to that found in other bats [Table S3.1]. 24,985 genes and pseudogenes were 
annotated in Raegyp2.0, which is similar to the number estimated by transcriptomic 
analysis (Lee et al. 2015; Hölzer et al. 2016) and the numbers in other bats [Table 3.3]. 
19,668 of the annotated genes were protein-coding genes and 2,380 were non-coding 
genes. 5,958 long non-coding RNAs were predicted with full support from transcript data 
and 340 tRNA models were predicted with tRNAscan-SE. 96.03% of predicted mRNAs 
were fully supported by transcriptomic or protein data. A total of 16,254 of predicted 
protein-coding genes (83%) had at least one protein aligning to a UniProtKB/SwissProt 
protein for over 95% of its length, which was higher than for any other bat annotated by 
the NCBI pipeline at the time. In addition, the number of the UniProtKB/SwissProt hits 
covered over 95% of their length by a predicted protein was similarly high (82%), 
indicating that the predicted proteins on Raegyp2.0 represent full-length models.  
Of the 19,668 protein-coding genes annotated in the genome, 317 genes have no 
associated gene labels or homolog in open reading frames from genomes of other species 
in RefSeq, and may represent novel ERB-specific genes. However, the median length of 
the protein product of these genes (257 amino acids) is significantly lower than the 
median length of all annotated proteins (498 amino acids). Thus, it remains a possibility 
that these genes have been previously identified in other species but are partial or poor 
models in Raegyp2.0 because of misannotation or local misassembly.  
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Species (Assembly name) 
Protein-coding 
genes 
Pseudogenes 
Non-coding 
genes 
Total 
Rousettus aegyptiacus 
(Raegyp2.0) 
19,668 2,937 2,380 24,985 
Pteropus vampyrus 
(Pvam_2.0) 
19,426 2,959 1,197 23,582 
Pteropus alecto 
(ASM32557v1) 
18,224 2,758 948 21,930 
Myotis lucifugus 
(Myoluc2.0) 
20,405 5,397 4,061 29,863 
Myotis brandtii 
(ASM41265v1) 
20,117 4,176 4,500 28,793 
Myotis davidii 
(ASM32734v1) 
18,941 4,387 3,213 26,541 
Miniopterus natalensis 
(Mnat.v1) 
18,235 3,224 1,534 22,993 
Eptesicus fuscus 
(EptFus1.0) 
18,427 4,125 52 22,604 
Rhinolophus sinicus 
(ASM188883v1) 
21,515 3,645 2,632 27,792 
Hipposideros armiger 
(ASM189008v1) 
19,083 3,797 2,945 25,825 
Pteronotus parnellii 
(ASM46540v1) 
N/A N/A N/A 20,357a 
Megaderma lyra 
(ASM46534v1) 
N/A N/A N/A 20,043a 
Eidolon helvum 
(ASM46528v1) 
N/A N/A N/A 20,455a 
Rhinolophus ferrumequinum 
(ASM46549v1) 
N/A N/A N/A 20,424a 
Table 3.3. Genes and pseudogenes in all available bat genomes in NCBI Genome 
database. 
Numbers of protein-coding genes, pseudogenes, and non-coding genes predicted in all 
available bat genomes in the NCBI Genome database by the NCBI Eukaryotic 
Annotation Pipeline. Annotation reports were accessed on 8/8/17. aFour bat genomes 
deposited in the NCBI genome database were not annotated by the NCBI Eukaryotic 
Annotation Pipeline. The number of total genes is the predicted number of gene models 
for these genomes (Parker et al. 2013) 
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3.4 A number of innate immune gene families are expanded in the ERB 
To gain insight into the evolutionary relationship of the ERB to other bats and to 
incidental hosts of MARV, we inferred homologous protein groups among the ERB and 
14 other mammals and constructed a maximum-likelihood phylogenetic tree of all 15 
species using single-copy orthologous genes [Figure 3.2]. As previously established, the 
closest taxon to bats among the taxa included in the analysis is the horse (Equus caballus) 
(Seim et al. 2013; Zhang et al. 2013).  
We performed gene family expansion and contraction analysis on inferred gene 
families and observed many more expanded families in microbats than megabats, similar 
to what has previously been shown (Zhang et al. 2013; Tsagkogeorga et al. 2017). 55 
gene families are significantly expanded in the ERB compared to the megabat ancestor 
[Figure 3.2, Table S3.1, Table S3.2]. Among the gene families that are significantly 
expanded in the ERB, some are absent from the PANTHER database and are classified as 
unlabeled families, while others are present in the PANTHER database, but remain 
uncharacterized. We manually corrected type I IFN gene family sizes after observing that 
several genes that were annotated as type I IFNs by the NCBI did not appear in our 
inferred gene families. Further exploration revealed that these additional IFNs get 
classified as single gene families or as unlabeled gene families because they consist of 
only bat IFNs. Tables S3.1 and S3.2 contain all the gene families with expansions and 
contractions in the ERB prior to and post IFN-correction, respectively. 
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Figure 3.2. Gene family expansion and contraction across a phylogenetic tree of 15 
mammalian species. 
A maximum likelihood tree based on 2,400 orthologous proteins was generated and used 
to infer expansion and contraction of 7,698 gene families. The number of expanded and 
contracted gene families is in blue and red, respectively. Numbers in black are the 
bootstrap evidence for partitions based on 1,000 bootstrap replicates. Images used under a 
creative commons license. MRCA: Most recent common ancestor. 
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3.5 Innate immune genes have experienced positive and relaxed purifying selection 
pressures in the ERB. 
To investigate whether evolution at the gene level could contribute to the unique 
phenotype of the ERB compared to other mammals, we studied disease-relevant immune 
genes for selection pressures. We included genes involved in dendritic cell maturation, 
induction and signaling of type I IFNs, and cytokine responses, since dysfunctions of 
these pathways have all been reported as contributors to the pathogenesis of MARV in 
primates. We also included genes in DNA damage response pathways, since adaptations 
in DNA damage responses during the selection for flight in bats have been hypothesized 
to influence immune responses in bats (for a full list of genes studied, see Table S5). 
Multiple innate immune response genes experience positive selection pressures along the 
ERB branch, including ISG15, an interferon-stimulated gene, IFNAR1, a subunit of the 
type I IFN receptor, and SIKE1, a negative regulator of the interferon response [Table 
3.4]. Since most genes do not experience strong positive selection pressures across their 
whole length, we also looked for relaxed purifying selection pressures. This analysis 
identified several more innate immune genes that experience a faster rate of evolution, 
including JAK2 and STAT3, components of the JAK/STAT signaling cascade, DDX58 
(RIG-I), a sensor of viral double-stranded RNA, and TLR8, a pathogen-sensing molecule 
[Table 3.4]. These results are consistent with those from similar analyses in P. alecto and 
M. davidii (Zhang et al. 2013). We mapped genes that experienced positive or relaxed 
purifying selection pressures onto pathways using IPA. We were able to observe 
examples of pathways apparently enriched for rapidly evolving genes, such as the NF-KB 
  
66
and IL-6 signaling pathways [Figure S3.1], though we did not test this hypothesis 
formally. 
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Symbol Gene ω0 ω1 FDR 
SIKE1 Suppressor of IKBKE 1 0.117 1.107b 1.85E-09 
ISG15 
Interferon stimulated gene 15 
ubiquitin-like modifier 
0.151 1.841b 3.01E-08 
PFN1 Profilin 1 0.161 2.003b 1.58E-05 
CD48 CD48 molecule 0.638 2.074b 1.62E-04 
IL1RL1 Interleukin 1 receptor like 1 0.417 1.246b 5.83E-04 
NQO1 
NAD(P)H quinone dehydrogenase 
1 
0.204 1.210c 6.23E-04 
IL17A Interleukin 17A 0.316 1.146b 2.22E-03 
LEP Leptin 0.360 2.289a 2.42E-03 
OSMR Oncostatin M receptor 0.534 1.053b 6.85E-03 
TNFRSF1A 
TNF receptor superfamily member 
1A 
0.346 1.133a 1.58E-02 
IFNAR1 
Interferon alpha and beta receptor 
subunit 1 
0.527 1.193c 4.64E-02 
DDX58 Dexd/h-box helicase 58 0.339 0.586b 5.77E-03 
TLR8 Toll like receptor 8 0.346 0.608b 1.82E-03 
NOD2 
Nucleotide binding oligomerization 
domain containing 2 
0.150 0.267b 1.02E-03 
LTBR Lymphotoxin beta receptor 0.314 0.803b 5.24E-04 
NFKB2 Nuclear factor kappa B subunit 2 0.083 0.324b 6.67E-12 
REL 
REL proto-oncogene, NF-kB 
subunit 
0.225 0.424b 1.11E-02 
RELA 
RELA proto-oncogene, NF-kB 
subunit 
0.093 0.424b 4.10E-11 
RELB 
RELB proto-oncogene, NF-kB 
subunit 
0.087 0.545c 8.31E-15 
RNASEL Ribonuclease L 0.538 0.906b 5.77E-03 
JAK2 Janus kinase 2 0.090 0.303c 1.60E-03 
STAT3 
Signal transducer and activator of 
transcription 3 
0.002 0.016d 4.72E-02 
Table 3.4. Positive and relaxed purifying selection in ERB immune genes. 
Evolution rates were estimated under several models, and the best fitting model was 
chosen. ω0 refers to the background rate of evolution and always includes non-bat 
species, but also includes some bat species under certain models. ω1 refers to the rate of 
evolution of the ERB gene but also includes other bat species under certain models. See 
Illustration 2.2 for full description of the models. a ω1 estimate under Model1a; 
b ω1 
estimate under Model1b; c ω1 estimate under Model1c; 
d ω1 estimate under Model 3; 
f 
FDR = False-discovery rate 
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Discussion 
We used a hybrid strategy combining both short- and long-read NGS technologies 
to generate a high-quality annotated genome for the ERB (Rousettus aegyptiacus), an 
asymptomatic host of MARV (Towner et al. 2009).  The genome assembly (Raegyp2.0) 
generated with this strategy has overall statistics comparable to those of other bat 
genomes, but has significantly higher contiguity. As a result, Raegyp2.0 captures 
repetitive regions more completely than other published bat genomes, allowing us to 
better resolve the gene organization of highly repetitive loci. We find that many genes 
families, including several associated with immune functions, have undergone 
evolutionary expansion, experienced positive selection pressures, or both. 
 
Supplemental Material 
Table S3.1. Repetitive content in Raegyp2.0 and in other bat genomes 
Kb: kilobases of genome sequence; TE: Transposable elements; LINE: Long-interspersed 
elements; SINE: Short-interspersed elements; LTR: Long-terminal repeats 
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Table S3.2. All expanded families in the ERB after correction of type I IFN family. 
Families designated as unlabeled (N/A in the PANTHER Family column) did not map to 
any gene families in the PANTHER database. Some PANTHER families have no  
PANTHER ID PANTHER Family P-value 
Family size in 
ERBs 
Family size 
in megabat 
ancestor 
PTHR11691 TYPE I INTERFERON <0.000001 42 20 
PTHR24249 
HISTAMINE RECEPTOR-
RELATED G-PROTEIN 
COUPLED RECEPTOR 
<0.000001 46 31 
UnlabeledFamily879 N/A <0.000001 11 1 
UnlabeledFamily2 N/A <0.000001 19 10 
PTHR22800 
C-TYPE LECTIN 
PROTEINS 
0.000002 32 24 
PTHR13069 UNCHARACTERIZED <0.000001 10 3 
PTHR23430 HISTONE H2A 0.000005 26 19 
UnlabeledFamily75 N/A <0.000001 6 1 
UnlabeledFamily28 N/A 0.000002 9 4 
PTHR11430 LIPOCALIN 0.00002 14 9 
PTHR23428 HISTONE H2B 0.000443 24 19 
PTHR24242 
G-PROTEIN COUPLED 
RECEPTOR 
0.00173 32 27 
PTHR11426 HISTONE H3 0.00043 14 10 
PTHR10903 
GTPASE, IMAP FAMILY 
MEMBER-RELATED 
0.00043 14 10 
PTHR12015 
SMALL INDUCIBLE 
CYTOKINE A 
0.005707 26 22 
UnlabeledFamily1195 N/A 0.000018 4 1 
PTHR23179 
T-CELL ACTIVATION 
RHO GTPASE 
ACTIVATING PROTEIN-
RELATED 
0.000437 7 4 
PTHR43605 FAMILY NOT NAMED 0.00082 8 5 
PTHR24147 FAMILY NOT NAMED 0.002086 10 7 
PTHR24225 
CHEMOTACTIC 
RECEPTOR 
0.002992 11 8 
PTHR14453 
PARP/ZINC FINGER 
CCCH TYPE DOMAIN 
CONTAINING PROTEIN 
0.004086 12 9 
PTHR24381 FAMILY NOT NAMED 0.012367 17 14 
PTHR23097 
TUMOR NECROSIS 
FACTOR RECEPTOR 
SUPERFAMILY 
MEMBER 
0.030684 24 21 
UnlabeledFamily1111 N/A 0.000537 3 1 
UnlabeledFamily1391 N/A 0.000537 3 1 
UnlabeledFamily104 N/A 0.000537 3 1 
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PTHR42912 FAMILY NOT NAMED 0.002615 4 2 
UnlabeledFamily1030 N/A 0.002615 4 2 
PTHR14389 FAMILY NOT NAMED 0.006001 5 3 
UnlabeledFamily5 N/A 0.006001 5 3 
PTHR16529 FAMILY NOT NAMED 0.01049 6 4 
PTHR19051 
KERATIN-ASSOCIATED 
PROTEIN 
0.03625 10 8 
UnlabeledFamily1329 N/A 0.016374 2 1 
UnlabeledFamily1272 N/A 0.016374 2 1 
PTHR16797 
FACTOR VIII-
ASSOCIATED GENE 1 
0.016374 2 1 
PTHR23299 METALLOTHIONEIN 0.016374 2 1 
UnlabeledFamily1206 N/A 0.016374 2 1 
UnlabeledFamily1198 N/A 0.016374 2 1 
UnlabeledFamily1205 N/A 0.016374 2 1 
PTHR34929 FAMILY NOT NAMED 0.016374 2 1 
UnlabeledFamily1163 N/A 0.016374 2 1 
PTHR35154 FAMILY NOT NAMED 0.016374 2 1 
PTHR24302 FAMILY NOT NAMED 0.032751 3 2 
PTHR14819 GTP-BINDING 0.032751 3 2 
UnlabeledFamily18 N/A 0.032751 3 2 
PTHR22801 LITHOSTATHINE 0.032751 3 2 
PTHR31943 
INTERLEUKIN-28 AND 
29 
0.032751 3 2 
PTHR15036 FAMILY NOT NAMED 0.032751 3 2 
PTHR31577 FAMILY NOT NAMED 0.032751 3 2 
PTHR15478 
PLECKSTRIN 
HOMOLOGY-LIKE 
DOMAIN, PQ-RICH 
PROTEIN 
0.032751 3 2 
PTHR12021 FAMILY NOT NAMED 0.049047 4 3 
PTHR10836 
GLYCERALDEHYDE 3-
PHOSPHATE 
DEHYDROGENASE 
0.049047 4 3 
PTHR11199 STROMAL ANTIGEN 0.049047 4 3 
PTHR24075 FAMILY NOT NAMED 0.049047 4 3 
PTHR14845 FAMILY NOT NAMED 0.049047 4 3 
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Table S3.3. All expanded families in the ERB before correction of type I IFN family. 
Families designated as unlabeled (N/A in the PANTHER Family column) did not map to 
any gene families in the PANTHER database. 
 
PANTHER ID PANTHER Family P-value 
Family size in 
ERBs 
Family size 
in megabat 
ancestor 
PTHR24249 
HISTAMINE RECEPTOR-
RELATED G-PROTEIN 
COUPLED RECEPTOR 
<0.000001 46 31 
UnlabeledFamily879 N/A <0.000001 11 1 
UnlabeledFamily2 N/A <0.000001 19 10 
PTHR13069 UNCHARACTERIZED <0.000001 10 3 
UnlabeledFamily75 N/A <0.000001 6 1 
PTHR22800 
C-TYPE LECTIN 
PROTEINS 
0.000002 32 24 
UnlabeledFamily28 N/A 0.000002 9 4 
PTHR23430 HISTONE H2A 0.000005 26 19 
UnlabeledFamily1195 N/A 0.000018 4 1 
PTHR11430 LIPOCALIN 0.000019 14 9 
PTHR11426 HISTONE H3 0.000429 14 10 
PTHR10903 
GTPASE, IMAP FAMILY 
MEMBER-RELATED 
0.000429 14 10 
PTHR23179 
T-CELL ACTIVATION 
RHO GTPASE 
ACTIVATING PROTEIN-
RELATED 
0.000435 7 4 
PTHR23428 HISTONE H2B 0.000441 24 19 
UnlabeledFamily104 N/A 0.000536 3 1 
UnlabeledFamily1111 N/A 0.000536 3 1 
UnlabeledFamily1391 N/A 0.000536 3 1 
PTHR43605 FAMILY NOT NAMED 0.000818 8 5 
PTHR24242 
G-PROTEIN COUPLED 
RECEPTOR 
0.001723 32 27 
PTHR24147 FAMILY NOT NAMED 0.00208 10 7 
UnlabeledFamily1030 N/A 0.00261 4 2 
PTHR42912 FAMILY NOT NAMED 0.00261 4 2 
PTHR24225 
CHEMOTACTIC 
RECEPTOR 
0.002983 11 8 
PTHR14453 
PARP/ZINC FINGER 
CCCH TYPE DOMAIN 
CONTAINING PROTEIN 
0.004075 12 9 
PTHR12015 
SMALL INDUCIBLE 
CYTOKINE A 
0.005688 26 22 
PTHR14389 FAMILY NOT NAMED 0.005989 5 3 
UnlabeledFamily5 N/A 0.005989 5 3 
PTHR16529 FAMILY NOT NAMED 0.010469 6 4 
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PTHR24381 FAMILY NOT NAMED 0.012335 17 14 
UnlabeledFamily1206 N/A 0.016356 2 1 
UnlabeledFamily1272 N/A 0.016356 2 1 
UnlabeledFamily1329 N/A 0.016356 2 1 
PTHR23299 METALLOTHIONEIN 0.016356 2 1 
PTHR35154 FAMILY NOT NAMED 0.016356 2 1 
UnlabeledFamily1198 N/A 0.016356 2 1 
PTHR34929 FAMILY NOT NAMED 0.016356 2 1 
PTHR16797 
FACTOR VIII-
ASSOCIATED GENE 1 
0.016356 2 1 
UnlabeledFamily1163 N/A 0.016356 2 1 
PTHR23097 
TUMOR NECROSIS 
FACTOR RECEPTOR 
SUPERFAMILY 
MEMBER 
0.030614 24 21 
PTHR24302 FAMILY NOT NAMED 0.032716 3 2 
PTHR14819 GTP-BINDING 0.032716 3 2 
PTHR31577 FAMILY NOT NAMED 0.032716 3 2 
UnlabeledFamily18 N/A 0.032716 3 2 
PTHR15036 FAMILY NOT NAMED 0.032716 3 2 
PTHR15478 
PLECKSTRIN 
HOMOLOGY-LIKE 
DOMAIN, PQ-RICH 
PROTEIN 
0.032716 3 2 
PTHR22801 LITHOSTATHINE 0.032716 3 2 
PTHR31943 
INTERLEUKIN-28 AND 
29 
0.032716 3 2 
PTHR19051 
KERATIN-ASSOCIATED 
PROTEIN 
0.036184 10 8 
PTHR10836 
GLYCERALDEHYDE 3-
PHOSPHATE 
DEHYDROGENASE 
0.048995 4 3 
PTHR12021 FAMILY NOT NAMED 0.048995 4 3 
PTHR11199 STROMAL ANTIGEN 0.048995 4 3 
PTHR14845 FAMILY NOT NAMED 0.048995 4 3 
PTHR24075 FAMILY NOT NAMED 0.048995 4 3 
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Figure S3.1. Examples of immune signaling pathways with multiple genes 
experiencing positive or relaxed purifying selection pressures in the ERB. 
Genes experiencing selection pressures (highlighted in pink) were mapped onto pathways 
in the Ingenuity Pathways Knowledge Base. The networks were generated through the 
use of and adapted from Ingenuity Pathway Analaysis. A. IL-6 signaling. B. NF-κB 
signaling. 
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CHAPTER FOUR: COMPARATIVE GENOMIC ANALYSIS OF BAT 
GENOMES REVEALS UNSUAL FEATURES OF MULTIPLE IMMUNE LOCI 
IN BATS. 
Portions of this chapter are © 2018 Elsevier Inc. and were originally published in 
Pavlovich, et al, “The Egyptian Rousette Genome Reveals Unexpected Features of Bat 
Antiviral Immunity” Cell (2018), DOI: https://doi.org/10.1016/j.cell.2018.03.070. 
Introduction 
Natural killer cells 
Natural killer (NK) cells are a key component of the immune response because 
they are capable of rapidly eliminating infected and cancerous cells by cytotoxicity.  NK 
cell-induced cytotoxicity is regulated by NK cell receptors that transmit inhibitory or 
activating signals upon binding their cognate ligands to suppress or initiate cytotoxicity 
on the appropriate target cells. Inhibitory and activating signals are integrated to 
determine whether NK cells execute their cytotoxic effect (Saunders et al. 2015). In 
mammals, NK cell receptors are encoded in two distinct gene complexes: the natural 
killer complex (NKC) contains killer lectin-like receptors (KLRs) such as CD94 (KLRD), 
NKG2-related genes (e.g. KLRC), and Ly49, while the leukocyte receptor complex 
(LRC) contains immunoglobulin superfamily proteins such as the ILT/LIR family and the 
killer cell immunoglobulin-like receptors (KIRs). Both complexes vary in gene content 
among species, encoding both inhibitory and activating receptors, and individual NK 
cells express a combination of inhibitory and activating receptors.  
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The best-characterized mechanism of NK cell activation is “missing-self” 
detection, where NK cells monitor the expression of MHC I molecules on target cells 
using monomorphic inhibitory receptors. Inhibitory receptors recognize canonical MHC 
class I molecules on target cells and signal via immunoreceptor tyrosine-based inhibitory 
motifs (ITIMs) in their cytoplasmic domains. Most of these receptors are highly 
conserved across species and interact with equally-conserved MHC molecules. 
Activating receptors recognize various ligands from infected, stressed, and malignantly 
transformed cells, and associate with signaling proteins DAP10 or DAP12 via a 
positively charged amino acid residue in their transmembrane domains to transmit signals 
that initiate cytotoxic responses (Koch et al. 2013). In general, NK cell receptors are 
either inhibitory or activating, with the exception of KIR2DL4 in humans and NKG2 
genes in lemurs, which contain both ITIMs and a positively charged transmembrane 
residue (Parham & Moffett 2013).  
NK cell receptors have undergone extensive diversification in many species 
because of the polymorphic nature of their MHC class I ligands, as well as evolutionary 
pressures to overcome viral evasion of NK cell receptor-mediated immunity (Brown & 
Scalzo 2008). This diversification process generally yields a set of conserved NK cell 
receptors and a set of variable receptors. Evolutionary analysis of the LRC and the NKC 
of various mammals has shown that different species may draw from either locus for their 
repertoire of variable NK cell receptors (Parham & Moffett 2013). Humans, cattle, and 
simian primates diversify KIR genes, while rodents and horses diversify Ly49 genes 
located in the NKC. Prosimian primates such as lemurs are the only known group of 
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species to diversify NKG2/CD94 genes on the NKC as variable receptors (Averdam et al. 
2009). 
MHC Class I genes 
While KIRs interact with classical MHC class I molecules (cMHCs), 
NKG2A/B/C and F receptors interact with HLA-E, a non-classical MHC class I molecule 
(ncMHC) that displays nonamers derived from the signal peptides of cMHCs. This 
mechanism is thought to allow NK cells to monitor the expression of cMHCs and deliver 
cytotoxic hits to cells lacking such expression (Yokoyama & Plougastel 2003). In 
humans, MHC class I genes are located in three areas referred to as the α, κ, and β 
duplication blocks, which are separated by framework regions containing multiple non-
HLA genes (Kulski et al. 2002; Kumánovics et al. 2003). HLA-E and its functional 
equivalent in mice, H2-Qa1, are located in the κ block. Unlike NKG2A/CD94 receptors, 
NKG2D forms homodimers that bind a number of MHC class Ib ligands, including 
MICA and MICB, and members of the ULBP family, which are upregulated in cells 
during infection and stress (Carapito & Bahram 2015; Molfetta et al. 2016). 
 
Type I interferons 
The type I IFNs make up a diversified multi-gene family, including subtypes like 
α, β, δ, ω, ε, and others, whose members all signal through the same receptor (Hoffmann 
et al. 2015). Upon binding to their receptor, type I IFNs activate the JAK-STAT signaling 
pathway, leading to the formation of a transcription complex called ISGF3. ISGF3 then 
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translocates to the nucleus and binds to IFN stimulated response elements (ISREs), 
leading to the transcription of ISGs that induce an antiviral response, control cell 
proliferation, and modulate cell death pathways, among other effects (Sadler & Williams 
2008; Schneider et al. 2014). Almost all nucleated cells can produce IFNs, and their 
production is stimulated by the recognition of pathogen-associated molecular patterns 
(PAMPs) by pattern recognition receptors (PRRs) within cells, though certain PRRs 
involved in IFN production are only found in subsets of leukocytes (McNab et al. 2015; 
Hoffmann et al. 2015).  
An evolutionary analysis of the type I IFN locus in multiple mammals shows that 
multiple paralogs have experienced purifying selection pressures, suggesting that despite 
all binding to and signaling through the same heterodimeric receptor complex 
(IFNAR1/2) multiple IFN subtypes make non-redundant contributions to immunity (Sang 
et al. 2014; Walker & Roberts 2009; Manry et al. 2011). This finding has been 
corroborated by functional studies; though the exact functional contribution for each IFN 
isn’t known, differences in the interaction of various IFN subtypes with the receptor are 
known to differentially induce downstream ISGs (Lavoie et al. 2011; Schreiber & Piehler 
2015) via differences in ternary complex stability, half-life, affinity for receptor subunits, 
and ligand-receptor recycling (Schreiber & Piehler 2015; Kalie et al. 2008; Thomas et al. 
2011). This outcome is further stratified by cell type, partly because of divergent 
expression levels of IFNAR1/2 on the surface of different cell types. As a result, a range 
of antiviral effects are possible. Clinically, IFN subtypes are used to treat different 
conditions; IFN-α preparations are used to treat hepatitis B, hepatitis C, and various 
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malignancies, while IFN-β is used to treat multiple sclerosis (van Boxel-Dezaire et al. 
2006; Gibbert et al. 2013). Subtypes can be non-redundant in viral immunity; a study that 
used monoclonal antibodies to neutralize murine IFN-β or multiple IFN-α subtypes in a 
mouse model of West Nile virus infection discovered an additive effect of subtypes 
(Sheehan et al. 2015). This effect can depend on the virus; even two strains may be 
differentially sensitive to particular IFN subtypes, as has been seen for mumps viruses 
(Markušić et al. 2014). It has also been shown that viruses can induce cells to produce 
specific subtypes, which may distinguish the outcomes of infection (Baig & Fish 2008; 
Hillyer et al. 2012; Thomas et al. 2014). 
The magnitude and nature of the IFN response also determine whether the 
resulting effects on the host are harmful or beneficial (Malireddi & Kanneganti 2013). 
For example, dysregulation of the type I IFN response has been implicated in the 
pathogenesis of multiple emerging viruses, including MARV (Caballero et al. 2016; 
Connor et al. 2015; Virtue et al. 2011).  
Results 
4.1 NKG2 natural killer cell receptors have expanded and diversified in the ERB, and 
display genetic signatures of unusual signaling. 
Gene family expansion and contraction analysis (Chapter Three) reveals that the 
C-type lectin family is significantly expanded in the ERB [Table S3.1, Table S3.2]. The 
C-type lectin family includes proteins containing C-type lectin domains (CTLDs), which 
bind carbohydrates in a calcium dependent way, as well as genes that contain C-type 
lectin-like domains that are homologous to CTLDs but do not actually bind carbohydrates 
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(Zelensky & Gready 2005). The expansion of the C-type lectin gene family in the ERB is 
due to a specific expansion of the NKG2 genes, which are a group of natural killer cell 
receptors that contain CTLDs but are not known to bind carbohydrates. 
We find no functional members of the LRC, but we do find a substantial number 
of NKG2 genes [Table S3.1, Table S3.2, Figure 4.1A], consistent with what was found 
in P. alecto (Papenfuss et al. 2012). From NCBI-based and manual annotations, we 
identified 14 NKG2A/B-like genes (referred to as NKG2-1 through NKG2-14, including 
four pseudogenes), one NKG2D-like gene, and one NKG2C-like gene. Remarkably, six 
of the ten putatively functional NKG2A/B-like genes simultaneously encode activating 
and inhibitory interaction motifs. Of the remaining genes, three encode only inhibitory 
motifs, and only one gene encodes an activating motif alone [Figure 4.1B]. No other 
potential NK cell receptor genes were found. While inhibitory NKG2 receptors signal via 
ITIMs in their cytoplasmic domains, activating CD94/NKG2 receptors transmit signals 
via a positively charged residue in their transmembrane domains. This residue recruits 
adaptor molecules that contain activating motifs, with a lysine residue associated with 
DAP12 recruitment, and an arginine residue associated with DAP10 recruitment. ERB 
NKG2 proteins with putative activating function show a strong preference for arginine at 
this location, suggesting that these receptors favor an association with DAP10 [Figure 
4.1B]. This transmembrane arginine is conserved in NKG2D in humans and in all the 
bats we studied [Figure 4.2]. Finally, ERB NKG2 genes are also fairly diverse in 
putative receptor binding sites [Figure 4.3].  
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To determine whether NKG2 genes are expressed, we queried previously 
published transcriptomic data (Lee et al. 2015), and found that the majority of these genes 
are expressed at low levels in peripheral blood mononuclear cells and secondary 
lymphoid organs [Figure 4.1C], similar to human baseline expression. But two 
receptors—NKG2-13 and NKG2-14—are expressed at higher levels in the same tissues. 
These NKG2 receptors have inhibitory signaling motifs, suggesting that inhibitory 
signaling dominates in uninfected bats.  
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Figure 4.1 Expansion of the NKG2 genes in the ERB.  
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A. CD94 and NKG2 genes in the natural killer complex in Raegyp2.0. Each arrow 
designates a scaffold sequence in the Raegyp2.0 genome. Not pictured are pseudogenes 
and non-coding genes. The ellipse indicates the presence of additional non-NKG2 genes 
on the same scaffold. The scaffolds containing the NKC locus in panel A are in order 
from top to bottom: NW_15493182.1, NW_15493451.1, NW_15493213.1, and 
NW_15494625.1.B. Multiple sequence alignments showing activating and inhibitory 
signaling motifs in NKG2 genes in humans and three bats. There were no putative 
functional bat NKG2 genes identified in P. alecto or M. davidii except NKG2-D. ITIM 
(immunoreceptor tyrosine-based inhibition motif) residues are in red, and the signal 
anchor residue lysine (K) or arginine (R) are in green and blue respectively. Dashes 
represent gaps in the alignment. C. Expression of putative functional NKG2 genes in 
transcriptomic data from ten tissues in an Egyptian rousette bat. Rows are ordered by 
highest average expression of transcripts across all tissues for a given gene. Expression is 
reported in log2(TPM), where TPM refers to transcripts per million. Data analyzed from 
Lee et al., 2015. 
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Figure 4.2 Alignment of the transmembrane domain of putative functional NKG2D 
proteins in humans and bats.  
Dashes indicate positions of diversity in the consensus sequence. The conserved arginine 
residue that serves as a signal anchor is shown in red. NKG2D-1 is shown for M. davidii, 
and NKG2D-2 is shown for M. lucifugus. 
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Figure 4.3 Alignment of human NKG2A and C and putative functional bat NKG2 
protein sequences.  
A. NKG2 residues that are known to contact CD94 in the human NKG2A protein (in 
orange), and B. NKG2 residues that are known to contact HLA-E/peptide in human 
NKG2A protein (in blue) (Kaiser et al. 2008). 
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4.2 CD94 receptors, the binding partners of NKG2 genes, exist in multiple copies in the 
ERB and are missing conserved cysteines. 
We also identified 5 diverse CD94-like genes. These additional genes presumably 
allow substantial combinatorial diversity among heterodimeric NKG2/CD94 receptors 
[Figure 4.1A, Figure 4.5]. Four of the five CD94 genes in the ERB lack two cysteines at 
position 58 and 59 that are highly conserved in multiple mammal species [Figure 4.4A]. 
These cysteines participate in the disulfide-mediated heterodimeric interaction between 
CD94 and NKG2 proteins in humans (Kaiser et al. 2008; Petrie et al. 2008), suggesting 
that these CD94 molecules might interact with their NKG2 co-receptors in an alternate 
way. To determine whether multiple CD94 genes are expressed in the ERB, including 
some of the unusual members that lack conserved cysteines, we examined the Lee et al. 
2015 dataset, and found that like the NKG2 genes, CD94 genes are also expressed in 
many tissues at low levels, particularly in peripheral blood mononuclear cells and 
secondary lymphoid organs [Figure 4.4B]. However, CD94-1, the only gene with intact 
cysteines at positions 58 and 59, is expressed at much higher levels than genes lacking 
the cysteines.  
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Figure 4.4 Expression and diversity of CD94 in the ERB. 
A. Multiple sequence alignments showing conserved cysteine residues in CD94 genes in 
humans and five bats. Pseudogenes are indicated with the letter p in protein name. 
Asterisks indicate missing residues from a partial P. vampyrus CD94. B. Expression of 
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CD94 genes in transcriptomic data from ten tissues in an ERB. Rows are ordered by 
highest average expression of transcripts across all tissues for a given gene. Expression is 
reported in log2(TPM), where TPM refers to transcripts per million. Data analyzed from 
Lee et al., 2015. 
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Figure 4.5 Multiple sequence alignments of binding sites in human CD94 and 
putative functional bat CD94 protein sequences 
Dots in alignments represent identity to the human protein sequence, while dashes 
represent gaps in the alignment. A. shows the CD94 residues that are known to contact 
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NKG2A in the human CD94 protein (in orange), and B. shows the CD94 residues that are 
known to contact HLA-E/peptide in human CD94 protein (in blue) (Kaiser et al. 2008). 
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4.3 NKG2-CD94 receptors are expanded and diversified in multiple species of bats. 
To determine whether NKG2/CD94 receptors are diversified across bats (both 
mega and microbats), we also examined the NKC in other bats in our analysis. All other 
bats have multiple NKG2-like genes, though some were not originally classified as C-
type lectins because of missing exons; P. vampyrus and P. alecto also have multiple 
CD94-like genes [Figure 4.6]. Each bat has one CD94 gene with canonical cysteine 
residues at position 58 and 59, [Figure 4.4A], and like the ERB, multiple bats have CD94 
genes without these residues. In addition, on a gene phylogram, CD94 genes lacking 
cysteines at positions 58 and 59 form a different subtree than CD94 genes with intact 
cysteines [Figure 4.8B]. Together these data suggest that these non-canonical CD94 
genes may encode proteins with alternative functions. Mouse and rat CD94 are capable of 
direct association with DAP12 or DAP10 via a lysine residue in their transmembrane 
domains (Koch et al. 2013), but the CD94 sequences from all bats we have examined 
have no lysine residues in their transmembrane regions, so are unlikely to associate 
directly with DAP proteins [Figure 4.7]. 
Phylogenetic analysis shows that NKG2 genes have undergone considerable 
diversification before and after the speciation of megabats [Figure 4.8A]. As with the 
ERB, the putative functional and truncated NKG2 genes in both megabats (P. alecto, P. 
vampyrus) and microbats (M. lucifugus, and M. davidii) contain ITIMs or both ITIMs and 
a positively charged transmembrane residue, suggesting that both inhibitory and 
activating signaling in these receptors is common among all bats in our analysis [Figure 
4.1B]. 
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Figure 4.6 Locus maps of the NKG2 and CD94 genes in the natural killer complex 
in four bat species. 
Each arrow designates a scaffold sequence in corresponding bat genome. Not pictured are 
unrelated pseudogenes and non-coding genes. The ellipse indicates the presence of 
additional non-NKG2 genes on the same scaffold. The scaffolds containing the NKC loci 
are, in order from top to bottom: P. vampyrus - NW_011888897.1, NW_011889578.1, 
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NW_011889241.1, NW_011889581.1, NW_011889318.1; P. alecto - NW_006431924.1, 
NW_006436696.1, NW_006429163.1, NW_006432008.1; M. davidii - 
NW_006299270.1, NW_006295002.1, NW_006281977.1, NW_006289839.1; M. 
lucifugus - NW_005871058.1, NW_005873184.1, NW_005874133.1. 
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Figure 4.7 Multiple sequence alignments of the transmembrane and cytoplasmic 
domains in multiple species of bats.  
A. Alignment of the transmembrane domain of CD94 in human, mouse, rat, and bats. The 
lysine (K) residue that serves as a signal anchor for DAP10 and DAP12 in rodents is 
shown in blue. This residue is not conserved in bat CD94 proteins. B. Alignment of the 
cytoplasmic domain of CD94 in human and bats. 
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Figure 4.8 Maximum likelihood phylogenetic tree of bat NKG2 and CD94 proteins 
and homologs in other species.  
Bootstrap evidence (percentage of 500 bootstrap replicates) is labeled on branches if 65 
or over. A. NKG2 proteins from the ERB are colored by predicted function. B. CD94 
proteins from the ERB are marked by red dots.  
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4.4 MHC molecules are expanded and widely distributed in the ERB genome and in other 
bat genomes. 
We hypothesized that the expansion of the NKG2 receptor family would be 
matched by an expansion of cMHCs or ncMHCs. Raegyp2.0 appears to lack the α and κ 
blocks [Figure 4.9A], as do P. alecto and E. fuscus (Ng et al. 2016). Consistent with an 
expansion, we find twelve MHC class I-like genes and seven pseudogenes in Raegyp2.0, 
none of which is discernible as the functional equivalent of HLA-E [Figure 4.9, Figure 
4.11]. Nonamers inferred bioinformatically from ERB MHC class I signal peptides are 
much less diverse than those observed in human or mouse, a pattern observed also in the 
gray mouse lemur [Figure 4.10B]. Only two MHC class I genes and two pseudogenes are 
located in the β block [Figure 4.9A]. Two MHC class I genes in Raegyp2.0 were found 
in genomic contexts apparently outside of the MHC class I region [Figure 4.9B]. Eight 
genes and five pseudogenes were identified on scaffolds that could not be further 
localized in the genome. These could potentially be allelic variants or additional genomic 
contexts for MHC class I genes. Examination of additional bat genomes also shows MHC 
class I genes outside the canonical MHC class I region, suggesting that dispersion of 
class I genes is not an assembly artifact but a common feature to many bats (data not 
shown). MICA and MICB were also not found in the MHC-I locus, though a candidate 
MICB ortholog was found outside of the MHC loci [Figure 4.9B]. Remarkably, the ERB 
and other bats appear to have two additional groups of NKG2D ligands, which are closest 
to ULBPs in humans [Figure 4.12]. Further investigation is needed to determine whether 
these genes functionally resemble ULBP or MIC family members. 
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To determine whether the MHC class I genes in Raegyp2.0 are expressed and 
potentially functional, we again examined our transcriptomic data. Many of the MHC 
class I genes in Raegyp2.0 are expressed across a wide range of tissues, including those 
located outside the canonical MHC locus [Figure 4.10A] such as MHC-11 and MHC-12, 
suggesting that they may function in the canonical self-detection role of cMHCs. 
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Figure 4.9. Characterization of the MHC class I region in Raegyp2.0.  
Locus maps of A. the MHC class I region, and B. MHC class I genes outside the 
canonical class I region in Raegyp2.0. Each arrow designates a scaffold sequence in the 
Raegyp2.0 genome; The scaffolds are, in order from top to bottom: panel A. 
NW_015494903.1, NW_015493289.1, and NW_015494931.1; panel B, column 1: 
NW_015493957.1, NW_015493337.1, NW_015493066.1, NW_015493167.1, 
NW_015493330.1, NW_015493360.1, and NW_015494802.1; B, column 2: 
NW_015494846.1, NW_015493471.1, NW_015492968.1, NW_015494660.1, and 
NW_015493352.1. Not pictured are non-MHC pseudogenes and non-coding genes. The 
ellipse indicates the presence of additional genes on the same scaffold. Black - MHC 
class I genes, grey – non-MHC genes, dark blue – MICB, unfilled boxes – MHC class I 
pseudogenes. The α, κ, and β class I duplication blocks are shown in red, purple, and 
green respectively.  
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Figure 4.10. Expression and diversity of MHC class I genes in the ERB 
A. Expression of MHC class I genes in transcriptomic data from ten tissues in an ERB. 
Rows are ordered by highest average expression of transcripts across all tissues for a 
given gene. Expression is reported in log2(TPM), where TPM refers to transcripts per 
million. Data analyzed from Lee et al., 2015. B. Sequence logo plots showing the 
sequence diversity of predicted nonamer peptides derived from the signal sequences of 
MHC class I genes from human (H. sapiens), mouse (M. musculus), ERB (R. 
aegyptiacus), and the gray mouse lemur (M. murinus). The y-axis shows information 
content in bits, and the x-axis shows position in the nonamer. 
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Figure 4.11 Maximum likelihood phylogenetic tree of bat MHC class I proteins. 
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ERB proteins are marked in red, and human MHC class I proteins are used as an 
outgroup. Bootstrap evidence (percentage of 500 bootstrap replicates) is labeled on 
branches if 65 or over. 
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Figure 4.12 NKG2D ligands in bats. 
Maximum likelihood phylogenetic tree of bat and human NKG2D ligands or NKG2D 
ligand-like proteins. ERB sequences are shown in red. Bootstrap evidence (percentage of 
500 bootstrap replicates) is labeled on branches if over 65. Green – MILL and MIC-like 
proteins, purple – RAET1E-like proteins, blue – human ULBP proteins, yellow – two 
groups of bat proteins 
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4.5 Type I interferons are expanded and diversified in the ERB genome. 
We estimate 20 type I IFN genes in the megachiropteran ancestor (see Chapter 
Three). We manually inspected and re-annotated the 42 in-frame IFNs annotated in 
Raegyp2.0 by the NCBI pipeline, based on similarity to inferred P. vampyrus genes. 
Additional manual annotation (see Chapter Two) revealed a total of 46 putative 
functional genes in Raegyp2.0 [Table S3.1], including 12 IFN-α genes, one of each of 
the IFN-β, -ε, and -κ genes, nine IFN-δ genes, and 22 IFN-ω genes [Figure 4.13, Figure 
4.14, Figure 4.15]. The greatest expansion occurred in the IFN-ω subfamily, which has 
only one copy in humans and mice. Many of the IFN genes annotated in Raegyp2.0 are 
highly similar to each other, which could mean that some of the sequences represent 
alleles rather than genes. However, even if the number of genes is halved to account for 
the presence of all alleles, the locus still contains many genes and is not unusually 
contracted relative to other mammals. Together, these annotations reveal that the IFN 
locus is not contracted in all species of bats, and that certain species of bats like the ERB 
have many more IFN genes that can be used to form antiviral responses. 
Given previous reports of constitutive IFN expression in bats, we sought to 
determine whether the expanded IFN genes may be constitutively expressed. We 
examined available transcriptomic data and found limited baseline expression of these 
genes [Table S4.1]. To determine whether these IFNWs may be induced by viral 
infection, we infected immortalized ERB cells (RoNi) with the Cantell strain of Sendai 
virus, a known inducer of IFNs in other species. We observed induction of IFN-ω 
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transcripts [Figure 4.16], though at relatively low levels compared to IFN-β or IFN-α 
transcripts. 
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Figure 4.13 Locus map of the type I IFNs in Raegyp2.0.  
Each arrow designates a scaffold sequence in the Raegyp2.0 genome; the scaffolds 
containing the type I IFN locus are, in order from top to bottom – column 1: 
NW_015494712.1, NW_015494244.1, NW_015493479.1, NW_015493859.1, 
NW_015494258.1, NW_015492835., NW_015494622.1; column 2: NW_015493694.1, 
NW_015493581.1, NW_015493794.1, NW_015493974.1, NW_015494085.1, 
NW_015494371.1, NW_015494373.1, NW_015494147.1, NW_015494111.1, 
NW_015494299.1. Unfilled boxes indicate pseudogenes. Orange – IFNβ, blue – IFNω, 
red – IFNα, yellow – IFNδ, purple – IFNε, green – IFNκ. The single non-IFN gene within 
the locus (KLHL9) is in grey. Not pictured are non-coding genes. The ellipse indicates 
the presence of additional non-IFN genes on the same scaffold. 
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Figure 4.14 Maximum likelihood phylogenetic tree of bat type I IFN proteins and 
homologs in other species.  
ERB proteins are marked in red, with groups of closely related proteins collapsed. 
Bootstrap evidence (percentage of 500 bootstrap replicates) is labeled on branches if 65 
or over. 
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Figure 4.15 Phylogeny of ERB type I IFN proteins.  
Maximum likelihood phylogenetic tree of bat type I IFN proteins. Groups of proteins 
collapsed in Figure 4.14 are expanded and labeled. Bootstrap evidence (percentage of 500 
bootstrap replicates) is labeled on branches if over 65. 
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Figure 4.16 Sendai virus (SeV) infection of RoNi cells elicits an IFN response, 
including IFN-ω.  
RoNi cell monolayers were infected with SeV strain Cantell at an MOI of 1.0 or mock 
infected, and harvested for total RNA extraction and sequencing at 3, 8, and 24 hours. 
Sequencing data were quantified by IFN subtype in transcripts per million (TPM). Values 
plotted are the mean ± standard deviation of three replicates for each time point. IFN-ε 
and IFN-δ were not expressed. Adjusted p-values from unpaired t-test between SeV and 
mock: * <0.05, ** <0.005, *** <0.0005. Figure made by Catherine E. Arnold from 
experimental work done by Jonathan C. Guito and Elyse Nagle. 
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Discussion 
Few viruses are known to cause acute disease in bats, including those that cause 
profound, often lethal, disease in humans. The precise mechanism of this viral resistance 
is not known. One hypothesis that has been gaining acceptance is that bats present 
especially potent innate antiviral defenses compared to primates, controlling viral 
replication early in infection, and as a result, developing effective adaptive immune 
responses (Baker et al. 2013). Our results support this hypothesis, but also raise the 
possibility of enhanced infection tolerance. We discuss the evidence for this hypothesis 
below. However, definitive tests of these hypotheses await the development of further 
experimental reagents for cytometry and biochemical intervention. 
NK cell receptors 
NK cells are an important component of innate antiviral responses, and have been 
associated with survival of Ebola virus infection (Liu et al. 2017). The unique 
organization, structure, and increased signaling complexity of the NK cell receptors in 
multiple bats point to adaptations that are also consistent with the infection tolerance 
hypothesis. Our findings suggest that NKG2/CD94 receptors, which are more associated 
with an inhibitory response in other species, serve as the primary NK cell receptors in 
bats. Consistent with this, all but one of the NKG2A/B-like genes in the ERB have 
inhibitory motifs at the cytosolic tail. We also detected an expansion of CD94 genes, 
which makes the possible combinatorial diversity of heterodimeric receptors very large, 
as previously demonstrated for prosimians (Averdam et al. 2009). Since signal 
transmission occurs via a conserved set of residues, the additional combinational 
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diversity is likely to be primarily associated with the capacity to bind additional ligands 
or differentially interact with the same ligands, rather than greater signaling complexity.  
Greater diversity in ligand binding would provide the ability to better recognize 
alleles of MHC class I to recognize self for NK cell tuning and licensing, and also to 
distinguish a variety of pathogen mimics of MHC class I molecules (Parham & Moffett 
2013). Moreover, the KLRD variants missing conserved cysteines add an additional level 
of complexity to this interaction that needs further characterization once tools for 
isolating NK cells in bats are available. In other mammals, KLRC genes are also 
expressed on T cells and act as important modulators of their response and determinants 
of the outcome after viral infection. NKG2A has been shown to control the level of T cell 
activation during viral infection, preventing excessive activation and immunopathology 
in mice (Rapaport et al. 2015; Ely et al. 2014). Given the high baseline expression of 
inhibitory KLRC genes across multiple tissues in the ERB, an immune-inhibitory state 
associated with both NK cells and T cells may be present in Egyptian rousette bats in the 
absence of infection, though this remains to be confirmed with functional studies.  
A further striking feature of the NK cell receptor genes in the ERB and the other 
bats we studied is the signaling mode they are predicted to use. In genes with potential 
for activating signaling, an arginine residue is preferred [Figure 4.1B], suggesting DAP-
10, rather than DAP-12, recruitment (Koch et al. 2013). DAP-12 has been shown to be 
more efficient in activating cytokine production than DAP-10 (Lanier 2009). Thus, a 
potential preference for DAP-10 could mean that activating NK receptors in bats have 
adapted to be less potent inducers of cytokines, and thus less inflammatory.  
  
117
NK cell receptors that possess both inhibitory and activating domains are unusual 
across mammals. The only known genes with both functions are the single gene 
KIR2DL4 in humans and the NKG2 genes in lemurs (Parham & Moffett 2013). 
KIR2DL4 activation promotes robust cytokine secretion but not cytotoxicity (Kikuchi-
Maki et al. 2005).  It is possible that the ERB KLRC genes mimic the signaling of human 
KIR2DL4, though parallels between both receptors are difficult to make without 
functional assays. However, our genomic evidence suggests that NK cell receptors in bats 
are uniquely regulated, especially given the multiple changes in the signaling potential of 
these receptors, which are highly conserved in eukaryotes ranging from Drosophila to 
humans.  
 
MHC Class I genes 
The potential extended capacity of the KLRC/KLRD system to bind diverse 
ligands is accompanied by expansion of MHC class I genes outside of the canonical 
MHC locus. Among these expanded genes, there is no obvious bat ortholog of HLA-E, 
the ligand for NKG2/CD94 receptors in humans. A similar expansion and absence of a 
clear HLA-E ortholog has been observed in prosimians (Averdam et al. 2009).  If one of 
the MHC class I genes in Raegyp2.0 is functionally similar to HLA-E, then presenting a 
peptide from one MHC class I molecule would likely be interchangeable with presenting 
a peptide from another because predicted nonamers from class I genes in Raegyp2.0 are 
much less diverse than those in humans and mice [Figure 4E]. Thus, expression of MHC 
class I molecules would have to be dramatically decreased in order for “missing-self” 
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detection to occur. While functional orthologs cannot be inferred without functional 
assays, the large number of MHC genes encoded outside the canonical locus in the bats 
we studied [Figure 4.8B] may be suitable ligands for the expanded KLR genes. 
Distribution of the MHC genes across the genome might serve as a mechanism to 
generate redundancy as different KLRC receptors might interact with distinct MHC class 
I genes. This could potentially result in a higher activation threshold for NK cells. 
Type I IFNs 
Bats may tolerate viral infections to a greater extent by minimizing the 
proinflammatory effectors that promote damage to the host in many viral infections. Type 
I IFNs are induced very early in viral infection and act by inducing effectors encoded by 
ISGs. Different IFN subtypes specifically interact with the common IFN receptor 
inducing a distinct spectra of ISGs with different antiviral potencies (Hoffmann et al. 
2015). The magnitude and nature of the IFN response determine whether the resulting 
effects on the host are harmful or beneficial (Malireddi & Kanneganti 2013). For 
example, dysregulation of the type I IFN response has been implicated in the 
pathogenesis of multiple emerging viruses, including MARV (Caballero et al. 2016; 
Connor et al. 2015; Virtue et al. 2011). 
Although IFN gene families differ substantially across mammals (Secombes & 
Zou 2017), the extensive expansion of IFN-ω genes in the ERB to almost two dozen 
genes is striking. This expansion is dramatically different from what was observed in P. 
alecto (Zhou et al. 2016), but is consistent with the expansion in P. vampyrus (Kepler et 
al. 2010). A wider variety of signaling mediators may provide the ERB greater flexibility 
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to develop a more nuanced antiviral response. It is also possible that different IFN-ωs 
may complement and/or synergize with each other.  
We observed IFN-ω gene induction in RoNi cells after Sendai virus infection, 
albeit at lower levels than IFNβ or IFN-α genes [Figure 4.14]. Given that Sendai virus is 
known to be a potent inducer of IFN-α and -β in particular, it is possible that different 
viruses or other stimuli may preferentially induce IFN-ω genes. Unlike P. alecto, R. 
aegyptiacus shows no evidence of constitutive IFN expression [Table S4.1]. Both bats 
are reservoirs for different emerging viruses of high virulence to humans, so it will be of 
great interest to determine whether these apparent differences in IFN expression represent 
distinct mechanisms of viral control by both bats species.  
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Supplemental material 
Table S4.1. Low baseline expression of type I IFN genes in uninfected ERB tissues. 
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CHAPTER FIVE: EXPANDED ERB TYPE I INTERFERONS HAVE A RANGE 
OF ANTIVIRAL POTENCIES, AND INDUCE A WIDE ARRAY OF ANTIVIRAL 
EFFECTORS. 
Portions of this chapter are © 2018 Elsevier Inc. and were originally published in 
Pavlovich, et al, “The Egyptian Rousette Genome Reveals Unexpected Features of Bat 
Antiviral Immunity” Cell (2018), DOI: https://doi.org/10.1016/j.cell.2018.03.070. 
Rationale 
Comparative analysis of IFN loci across vertebrates has documented an expansion 
of IFN genes in mammals, but this phenomenon is inconsistent in bats, with fewer genes 
(especially IFN-α) reported in the black flying fox (Pteropus alecto), but expansions of 
the locus reported in other bats (Zhou et al. 2016; Kepler et al. 2010). We have shown 
that the type I IFN locus is expanded in the ERB, with a specific expansion of IFN-ω 
genes (Chapter Four). This subtype is known to have potent antiviral activity in other 
species, including humans (who have a single IFN-ω), and additional genes may equip 
this bat with the ability to mount a balanced, less pathologic response to viral infection. 
However, the ISGs induced by these IFN-ω proteins are not known. To begin to 
understand the role of these genes in antiviral immune responses, we synthesized and 
purified recombinant ERB IFN-ω proteins. We pretreated both primary and immortalized 
ERB cells with these recombinant proteins and characterized the resulting transcriptional 
responses, as well as their antiviral potency and efficacy. 
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Results 
5.1 The 22 members of the IFN-ω subfamily in the ERB are divided into five phylogenetic 
clades. 
In Chapter Four, we learned that the Raegyp2.0 genome sequence contains 22 
IFN-ω genes. On close examination, many of these genes are highly similar to each other, 
and a few are completely identical at the nucleotide level. To help identify candidate 
genes for exploration with experimental studies, we constructed a gene phylogram of 
ERB IFN-ωs, and find that the 22 genes are divided into five clades [Figure 5.1]. The 
IFNAR1 and IFNAR2 binding sites on IFNs broadly, and on IFN-ω specifically, have 
been well-characterized for humans, (Thomas et al. 2011). From this structural work, we 
know that some sites are conserved among IFNs as “anchor” residues for receptor 
binding, and other sites are variable and dictate the functional differences observed 
between different IFNs. We annotated the broad collection of residues that participate in 
receptor binding on all 22 proteins using the NCBI conserved domain database search 
(See Chapter Two). We found that while proteins within a clade have high identity at 
these receptor-binding sites, these sites are much less conserved between clades [Table 
5.1]. We picked candidate genes from each clade and further examined specific residues 
that have been identified as functionally important in a crystal structure of the human 
IFN-ω/IFNAR1/IFNAR2 ternary protein complex (Thomas et al. 2011). The anchor 
residues are fairly well conserved between the human protein and bat proteins, but 
several variable sites have unique amino acids in every protein [Figure 5.2]. This 
suggests that the five phylogenetic clades of ERB IFN-ωs are likely to interact with the 
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receptor complex with differing affinities, potentially resulting in different downstream 
effects.  
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Figure 5.1. Phylogenetic tree of ERB IFN-ω proteins. 
A maximum likelihood tree of ERB IFNω proteins. The tree was constructed in RAxML 
and formatted in MEGA v7. Bootstrap evidence (percentage of 100 bootstrap replicates) 
is labeled on branches if over 65. Candidate IFN-ω proteins from each clade that were 
chosen for follow-up experimental work are labeled in red. 
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Clade 1 2 3 4 5 
1 - - - - - 
2 59.6 95.7 - - - 
3 68.1 63.8 - - - 
4 70.2 66.0 80.9-83.0 95.7-100 - 
5 72.3-76.6 59.6-61.7 74.5-78.7 78.7 95.7-100 
 
Table 5.1 Percent identity at all potential receptor-binding sites between and within 
ERB IFN-ω clades. 
Each entry shows the percent identity between members of different clades at IFNAR1 
and IFNAR2 binding sites. Percent identity is calculated as the total number of 
differences divided by the total number of binding sites. If multiple percent identities are 
shown, the values represent the minimum and maximum percent identities between 
individual clade members. 
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Figure 5.2. Multiple sequence alignment of representative bat IFN-ω proteins 
showing conserved and divergent putative receptor binding residues. 
Predicted signal sequences were cleaved for each protein. Annotations and putative 
receptor binding sites are based on structural work on the human IFN-ω/receptor ternary 
complex (Thomas et al. 2011). Residues important for interacting with IFNAR1 are 
highlighted in green, and residues that interact with IFNAR2 are highlighted in orange. 
 
  
127
5.2 Recombinant ERB type I interferons exhibit different antiviral potencies in bat cell 
lines and in primary cells. 
We next wanted to examine whether ERB IFN-ω proteins retain the canonical 
function of type I IFNs as antiviral proteins. Based on the genome annotations, we 
designed plasmids to encode IFN-β and one candidate member of each IFN-ω clade 
(IFN-ω1, 3, 4, 9, and 12) with a C-terminal tag of six histidines (6x-His) (see Chapter 
Two), and transfected them into 293F cells in a serum-free system to synthesize 
recombinant proteins. As a control, we also synthesized an unrelated 6x-His-tagged 
protein (PA-D1) of similar size. Proteins were purified via 6x-His tag binding to separate 
nickel columns, and all preparations were examined for successful expression by Western 
blot, and for purity by silver staining. All proteins were successfully expressed; however, 
IFN-ω1 was not secreted in human or bat cell supernatants likely because of an 
unsuitable signal sequence, and was not used for further studies (data not shown).  
We pretreated RoNi/7 cells with different concentrations of IFNs (0.01 to 100 
ng/mL), UIFN, or the 6x-His tagged control protein for 4 or 8 hours, and then infected 
them with vesicular stomatitis virus encoding eGFP (VSV-eGFP) at an MOI of 0.05. 
Consistent with a bona-fide antiviral function, all recombinant IFN-ωs block infection 
with VSV-eGFP. However, different IFNs have different potencies of antiviral effect, 
with some proteins exhibiting antiviral activity only at the highest concentration, while 
others are antiviral at nearly every tested concentration [Figure 5.3].  
Given that some protein preparations were not as pure as others, we focused on 
the two most pure IFN preparations—IFN-ω4 and IFN-ω9—to ensure that unrelated 
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proteins that bound non-specifically to the nickel column were not having an effect on 
antiviral function [Figure 5.4]. We also increased the viral MOI to 0.1 to emphasize 
quantitative differences in antiviral effect. Remarkably, IFN-ω9 is effective at 
concentrations a hundred-fold less than IFN-ω4 after 4 hour treatment, and even lower 
concentrations after 8 hour treatment [Figure 5.5]. We repeated this experiment in 
primary ERB fibroblasts, and found a similar pattern, with both IFNs considerably more 
effective despite an MOI of 50 [Figure 5.6]. 
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Figure 5.3. Antiviral effect of recombinant ERB IFN-β and -ω proteins.  
RoNi cells were treated with recombinant IFN-β1 (rIFN-β1), IFN-ω3, 4, 9, 12, or an 
unrelated protein (rPA-D1) for A. 4 hours or B. 8 hours, infected with VSV-eGFP at an 
MOI of 0.05, and imaged for eGFP expression 1 day post infection on a fluorescent 
microscope at 10x magnification. 1000 U of UIFN was used as a positive control. Higher 
concentrations of every IFN inhibit viral replication, with large differences in potency 
between IFNs. Images are from a single experiment. All images shown with 20% 
increased brightness and 20% increased contrast. 
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Figure 5.4. IFN-ω4, IFN-ω9, and PA-D1 preparations contain 6xHis-tagged 
recombinant proteins and few non-specific proteins. 
Proteins in clarified 293F cell supernatants were purified using affinity chromatography, 
dialyzed into PBS, and evaluated by A. silver stain for purity (100 ng/well), and by B. 
Western blot for His-tag specificity (250 ng/well). The control protein (D1) preparation 
contains a second, smaller protein, likely because of a second suitable downstream 
translation start site, but this protein is not His-tagged. 
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Figure 5.5. Antiviral effect of recombinant ERB IFN-ω4 and IFN-ω9.  
RoNi cells were treated with recombinant IFN-ω4 (rIFN-ω4), IFN-ω9, or an unrelated 
protein (rPA-D1) for A. 4 hours or B. 8 hours, infected with VSV-eGFP at an MOI of 
0.1, and imaged for eGFP expression 1 day post infection on a fluorescent microscope at 
10x magnification. 1000 U of UIFN was used as a positive control. Higher concentrations 
of both IFNs inhibit viral replication, with large differences in potency between IFNs. 
Images are representative of multiple independent experiments. 
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Figure 5.6. Antiviral effect of recombinant ERB IFN-ω4 and IFN-ω9 on primary 
bat cells.  
Primary ERB fibroblasts were treated with recombinant IFN-ω4 (rIFN-ω4), IFN-ω9, or 
an unrelated protein (rPA-D1) for 6 hours, infected with VSV-eGFP at an MOI of 50, and 
imaged for eGFP expression 1 day post infection on a fluorescent microscope at 10x 
magnification. 1000 U of UIFN was used as a positive control. Primary cells appear to 
respond to IFN better than immortalized RoNi cells. Images are representative of two 
independent experiments. 
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5.3 IFN-ω9 induces many more downstream genes than IFN-ω4. 
Given the observed difference in antiviral potency between IFN-ω4 and IFN-ω9, 
we next wanted to compare the downstream ISGs they induce. We pretreated RoNi cells 
with UIFN, or three different concentrations of IFN-ω4, IFN-ω9, or D1 for 4 hours or 8 
hours and collected RNA. We performed total RNA sequencing and pairwise differential 
gene expression analysis (see Chapter Two). First an ANOVA-like test was used to 
compare each treatment (D1, IFN-ω4, IFN-ω9) to every other treatment. Then, each IFN 
treatment was contrasted with the appropriate control treatment; IFN-ω treated samples 
were compared to D1 treated samples at the same concentration and time point. Separate 
from this analysis, UIFN treated samples were compared to untreated treated samples at 
the same time point. The total numbers of genes that passed our significance criteria 
(ANOVA FDR ≤ 0.05; pairwise log2 fold change > 1, pairwise p-value ≤ 0.05/3) are 
reported in Figure 5.7.  
Concentrations of IFNs at 4 or 8 hours that were not observed to be antiviral in 
our VSV-eGFP assay induced very few genes. In contrast, concentrations known to be 
antiviral induced many more genes. In general, similar numbers of genes were induced 
by all treatments at 4 and 8 hours. We compared the numbers of genes induced by IFN-
ω9 and -ω4 [Figure 5.8]. At both time points, 1ng/mL of IFN-ω9 induced many more 
genes than 1ng/mL of IFN-ω4, and there were only three genes induced only by IFN-ω4. 
A higher concentration of IFN-ω4 induced additional genes, though again, very few of 
these genes were unique to IFN-ω4 treatment. When all time points and concentrations 
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were combined, IFN-ω4 treatment induced only 5 unique genes, while IFN-ω9 treatment 
induced 54 unique genes. 
 We next compared the expression levels of the genes induced by both IFNs. At a 
low concentration of 1 ng/mL, IFN-ω9 treatment resulted in statistically significant 
greater expression of 210 of the 229 genes that rejected the null in the ANOVA test at 4 
hours, and 105 of the 143 genes at 8 hours of treatment [Figure 5.9A, Figure 5.10A]. In 
contrast, at a high concentration of 100 ng/mL, the log2 fold change was very similar 
between IFN-ω4 and IFN-ω9 treatments [Figure 5.9B, Figure 5.10B], with only 10 and 
12 genes induced more highly in IFN-ω9 at 4 and 8 hours respectively. We also 
compared genes induced by IFN-ωs and UIFN. With only one exception, every gene that 
was induced by UIFN was also induced by at least one of the IFN-ωs at one of the time 
points or concentrations tested. 54 genes were induced only by IFN-ω9, while five were 
induced only by IFN-ω4.  
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Figure 5.7 Numbers of differentially expressed genes in each treatment group.  
A. The total number of genes that rejected the null in the six ANOVA-like tests. B. The 
number of DEG under each treatment compared to control after pairwise comparisons of 
genes that passed significance criteria in the ANOVA-like test and p ≤ 0.05/3 in the 
pairwise test.  
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Figure 5.8. Comparing genes induced by IFN-ω4 and IFN-ω9 across time of 
treatment and concentration. 
Each Venn diagram shows the overlap in differentially expressed genes (ANOVA FDR ≤ 
0.05, pairwise log2 fold change > 1, pairwise p-value ≤ 0.05/3) for IFN-ω4 and IFN-ω9 
treated samples at a given concentration and time. The combined diagram shows the 
overlap between genes that were differentially expressed at any concentration or time for 
IFN-ω4 and IFN-ω9 treated samples. Only upregulated genes are shown. 
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Figure 5.9. Expression of genes that were differentially expressed in IFN-ω treated 
samples at 4h. 
The heatmaps show the relative log2 fold change (compared to D1 treatment) of genes 
that were differentially expressed by ANOVA analysis in samples treated with A. 
1ng/mL or B. 100 ng/mL of IFN-ω4 or -ω9. Only genes with FDR ≤ 0.05 are shown.
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Figure 5.10. Heatmaps of genes that were differentially expressed IFN-ω treated 
samples at 8h. 
The heatmaps show the relative log2 fold change (compared to D1 treatment) of genes 
that were differentially expressed by ANOVA analysis in samples treated with A. 
1ng/mL or B. 100 ng/mL of IFN-ω4 or -ω9. Only genes with FDR ≤ 0.05 are shown.
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Figure 5.11. Impact of time and concentration on number of differentially expressed 
genes for a given IFN-ω.  
Venn diagrams showing the overlap in differentially expressed genes between A. 
different treatment times or B. different concentrations of a given IFN-ω. Only 
upregulated genes were included. 
  
144
 
 
Figure 5.12. Genes induced by ERB IFN-ω and not UIFN. 
Venn diagrams show the overlap in genes induced by IFN-ω and UIFN. Only upregulated 
genes were included. Combined IFN-ω refers to genes that were differentially expressed 
in any IFN-ω treated sample (any concentration, any time point, either IFN-ω4 or -ω9). 
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Discussion 
Given the large expansion in the type I IFN ω subfamily in ERBs, we sought to 
examine members of this family to gain insight into the contributions of these proteins to 
ERB antiviral immunity. Based on a gene phylogeny and diversity at putative receptor 
binding sites, we expected a minimum of five functional groups of IFN-ω proteins, and a 
VSV-eGFP antiviral assay confirmed that at least one member of four of these groups are 
functional.  
Along with our genetic data, the results of the antiviral assay are consistent with 
our hypothesis that all IFN-ωs are not equal. The difference in potency among the tested 
IFNs was dramatic, with hundred-fold differences between IFN-ω4 and IFN-ω9. IFN-ω9 
induced more genes than IFN-ω4 under every tested condition, and at low concentrations, 
IFN-ω9 induced more genes and greater levels of the same genes than IFN-ω4. This is 
consistent with the results of the antiviral assay; at high concentrations, both IFNs protect 
RoNi cells from viral infection, while at lower concentrations, only IFN-ω9 is protective.  
 On the other hand, the high overlap in differentially expressed genes and 
similarity in level of gene expression between IFN-ω4 and -ω9 suggest that these proteins 
could be redundant at high concentrations. Nevertheless, both proteins induce a number 
of unique genes, and these are furthermore distinct from those induced by UIFN. It 
remains to be determined whether these genes do provide additional flexibility in immune 
responses as hypothesized in Chapter Four. 
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CHAPTER SIX: CONCLUDING REMARKS 
Portions of this chapter are © 2018 Elsevier Inc. and were originally published in 
Pavlovich, et al, “The Egyptian Rousette Genome Reveals Unexpected Features of Bat 
Antiviral Immunity” Cell (2018), DOI: https://doi.org/10.1016/j.cell.2018.03.070. 
Overview 
In this dissertation, we sought to investigate immune features that may contribute 
to the unusual ability of bats to host viruses that are nonpathogenic in bats but cause 
severe disease in humans.  With this goal in mind, we focused on the Egyptian rousette 
(R. aegyptiacus). Egyptian rousettes are known to host MARV and have been linked to 
specific transmission events of the virus to humans, yet they remain poorly characterized 
with regard to antiviral immune responses. To facilitate studies of this species, we first 
generated a high-quality genome sequence for the ERB, using multiple next-generation 
sequencing technologies to maximize the contiguity of the genome. We carried out 
several benchmarking tests to compare this genome to previously generated genomes 
sequences for other bat species.  
We then used this genome sequence and its associated annotations to generate 
hypotheses about bat immunity by exploring the evolution of immune genes and gene 
families both in the ERB and in bats more broadly. We focused on some of the key 
findings of this comparative genomic analysis, including findings related to NK cell 
receptors, MHC class I genes, and type I IFNs, and characterized them in depth with 
genetic data. Finally, we took one of these observations—the type I IFN expansion—and 
used our genetic evidence to design and conduct in vitro experiments to determine 
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whether our findings may have functional implications for immune responses in Egyptian 
rousette bats. 
 
Summary of key findings 
In Chapter Three, we sequenced, assembled, and annotated a de novo genome sequence 
for the Egyptian rousette bat. The key findings are: 
- Using long and short-read sequencing data with our assembly pipeline we 
produced a genome sequence that is estimated to cover 90% of the full Egyptian 
rousette genome. Raegyp2.0 has comparable numbers of annotated genes to other 
genomes and no major mis-assemblies, and is additionally more contiguous than 
any other bat genome currently available. 
- Several innate immune genes and gene families experience selection pressures 
and evolve at faster rates in the ERB. These include genes that evolve at similar 
rates in all bats, those that evolve at different rates in Yinpterochiroptera and 
Yangochiroptera species, and those that evolve differently in the ERB compared 
to any other bat we examined. 
In Chapter Four, we took some of the gene families that we identified as unusually 
expanded in Chapter Three, and examined them in detail. The key findings are: 
- NKG2/CD94 protein heterodimers likely serve as the main source of NK cell 
receptors in bats, given the absences of KIR and Ly49-like genes in multiple bat 
genomes. 
- Both NKG2 and CD94 genes have duplicated and diversified in the ERB, and 
given their heterodimeric assembly, an unusually large repertoire of receptors is 
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available to this species of bat. This is also the case in other species we examined, 
though limited contiguity of these regions in other bat genomes prevented us from 
annotating more than a handful of genes. 
- Many of the NKG2 genes we annotated have residues that could contribute to 
inhibitory or activating downstream signaling. The proteins with putative 
activating function largely possess a residue that is associated with recruitment of 
a specific downstream adaptor molecule, DAP10. Though not extensively 
characterized, DAP10 is believed to be less effective at leading to cytokine 
secretion in NK cells. 
- CD94 proteins in multiple specie s of bats are missing residues that are conserved 
in multiple mammals because of their structure importance for assembly of the 
heterodimeric receptor.  
- While no clear ligand for the NKG2/CD94 system is obvious, the ERB also 
possess multiple MHC class I genes, most of which are outside the canonical 
MHC class I region. These extra-locus genes are expressed in multiple bat tissues. 
- The type I IFNs are remarkably expanded in the ERB compared to humans and 
other bats, highlighting the divergence of immune loci even within the same 
taxonomic family. We see no evidence for constitutive expression of any IFNs in 
this bat. 
- Most of the IFN locus in the ERB consists of IFN-ω genes, which, like other type 
I IFNs, are associated with antiviral function in other species.  
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In Chapter Five, we followed up on the extensively duplicated IFN-ω subfamily and 
examined the function of candidate IFN-ω proteins in vitro. The key findings are: 
- Although the IFN-ω subfamily has 22 members in the ERB, considerable 
sequence identity at inferred receptor binding sites suggests that there are five 
functionally different phylogenetic clades. 
- Recombinant IFN-ω proteins display antiviral function against VSV-eGFP in both 
primary and immortalized ERB cells. 
- Different IFN-ω proteins have differing antiviral potencies. However, in general, 
longer exposure to IFN prior to infection results in greater antiviral efficacy even 
at low IFN concentrations, presumably because of a second wave of IFN 
induction or higher concentrations of antiviral ISGs. 
- At low concentrations, IFN-ω9 induces more genes and higher amounts of the 
same genes when compared to IFN-ω4, which may explain their differences in 
potency. However, at high concentrations these proteins have very similar though 
not identical transcriptional responses. 
- ERB IFN-ωs induce many more genes than UIFN. 
 
Significance 
This dissertation has several areas of significance. First, we envision that the work 
described in this dissertation will facilitate studies of MARV in its natural host and 
provide the foundation for designing the necessary reagents to examine bat immunology 
more thoroughly with the eventual goal of discovering adaptations in Egyptian rousette 
bats that allow them to avoid MVD pathology. Raegyp2.0 has already been utilized as a 
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resource for RNA-seq-based investigation of bat responses to filovirus infection in vitro 
(Hölzer et al. 2016). Second, this dissertation also contributes to an understanding of the 
evolution of innate antiviral defense systems and of bats as reservoir hosts of emerging 
pathogens. Our findings identify adaptations that could provide less pathogenicity or 
increased antiviral function. For example, we identify several genetic adaptations in NK 
cell receptors in bats that could be characteristic of an inhibitory immune state. However, 
we also observe many additional type I IFNs, which are known to have potent antiviral 
effects. The third area of significance addressed in this dissertation is related to the 
complexity of type I IFNs, especially IFNs that are not extensively characterized. Given 
the large expansions of the IFN repertoire in mammalian lineages, the possible 
complexity and tunability of IFN responses to viral infection is greatly underappreciated. 
We began to examine this complexity in the Egyptian rousette bat and found differences 
between IFNs that support the hypothesis that the considerable duplications in the IFN 
locus may have functional relevance for antiviral responses.  
Finally, by generating a de novo genome for a species belonging to the highly 
diverse order Chiroptera, this dissertation adds to a growing body of knowledge 
regarding mammalian genomics and evolutionary biology. One such advance is the 
insight gained regarding the commonalities and differences specifically among bats, 
including those that are reservoirs for viruses that infect humans and those that are not 
known to serve as hosts of human pathogens. Raegyp2.0 has been successfully used by us 
and others to identify genetic characteristics related to the unique physiological 
adaptations of bats (Tsagkogeorga et al. 2017). We observe immune genes that 
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experience selection pressures in certain bat lineages but not others. Similarly, we find 
expansions of gene families in some bats but contractions in others.  
Study limitations and future directions 
This study has several limitations that should be considered when interpreting the 
findings. While Raegyp2.0 is currently the most contiguous bat genome available, we are 
still missing 10% of the genome, a considerable amount of sequence. This limitation is 
common not only to mammalian genomes (because of complex genome characteristics) 
but also to many non-mammalian genomes that have been sequenced using next-
generation sequencing technologies. Our assembly pipeline is further complicated by a 
consensus calling method that may homogenize some highly repetitive regions. For 
example, five IFN-ω genes are identical at the nucleotide level in Raegyp2.0, and because 
of the consensus calling step, we cannot rule out the possibility that these genes are 
artificially homogenized rather than truly identical. However, it is reassuring that we 
recover similar numbers of genes compared to other mammalian de novo genome 
projects, and that highly conserved eukaryotic genes are well-annotated in Raegyp2.0. 
Nevertheless, it will be important to carefully examine immune gene loci of interest by 
baited sequencing of bacterial artificial chromosome (BAC) libraries to differentiate 
between alleles and gene duplications, and to order genes in immune loci. In addition, 
genomic data from additional Egyptian rousette bats will be helpful for confirming that 
these findings are relevant across the species and for exploring allelic diversity in these 
regions.  
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While our gene and gene family evolution studies generate several hypotheses, 
these studies are both limited by both the quality of other genomes and by NCBI 
annotations. Though the NCBI annotation is very robust, we observed instances where 
manual annotation revealed misannotations. For example, we found five additional type I 
IFN genes that were not annotated by the pipeline. Thus, many genes may have not been 
captured or may have poor gene models that cause them to be annotated as pseudogenes. 
We had to exclude additional species and genes in these analyses because of the poor 
quality of many of the gene models and in some cases, because of gaps in genomes that 
resulted in the absence of the gene annotation entirely.  
Based on these annotations, we closely examined genes within several gene 
families to generate hypotheses regarding function, but all of our hypotheses remain to be 
tested with careful experimental work. For example, we infer receptor binding sites on 
type I IFN genes based on previously published structures of human IFNs in complex 
with the receptor. While it is likely that there is considerable conservation between 
human and Egyptian rousette proteins in this regard, we have also observed signatures of 
positive selection pressure in one subunit of the ERB type I IFN receptor. Thus, these 
inferred binding sites may not be accurate and need to be confirmed with crystal 
structures. 
It is also important to keep in mind that we organized and labeled gene families 
based on sequence similarity. We chose this method based on our appreciation for the 
complex, non-linear modes of gene evolution, and it worked well in many cases, even 
identifying genes that were misannotated by the NCBI pipeline. However, given its 
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inherent reliance on parameters that dictate the similarity level at which to designate 
orthologous groups, this method was not free from error. For example, in the case of the 
type I IFN gene family, manual corrections had to be made. Additional ERB individuals 
also need to be studied to determine whether the expansions and contractions of gene 
families we observe are also seen in other members of the species.  
Regarding our experimental work, we chose specific genetic findings to follow up 
with in vitro studies because of the tools that were immediately available to us. We 
examined a subset of IFN-ωs (based on our annotations) by producing recombinant 
proteins in a human cell line and explored the function of these proteins in immortalized 
cells. While we were able to corroborate some of this work with studies in primary bat 
cells, it remains to be determined whether our findings pertain to authentic filovirus 
infection in vivo. We hypothesize that these expanded IFN-ω proteins may contribute to a 
more flexible antiviral response that may be useful to a host by avoiding excess 
pathology. Ideally, this hypothesis would be tested with multiple viruses, including 
viruses that naturally infect Egyptian rousette bats. It would also be informative to 
examine promoter and upstream transcriptional regulatory sequences for the various IFNs 
to learn whether transcription factor binding sites differ among IFNs. If different IFNs are 
under the control of different transcription factors, this would suggest that these IFNs are 
induced under different conditions. 
The exploration of additional hypotheses suggested by our genetic data is 
currently limited by the lack of bat-specific antibodies (for applications like flow 
cytometry and protein detection), knowledge of bat-specific cell markers, and availability 
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of recombinant cytokines for primary cell culture systems. For example, we hypothesize 
that NKG2 and CD94 receptors may be upregulated during infection. This is a difficult 
hypothesis to test because these molecules are believed to be restricted to NK and T cells, 
and reagents for sorting these cells from the peripheral blood of Egyptian rousette bats 
are not yet available. Moreover, antibodies to detect NKG2 and CD94 protein expression 
are also not available. 
Similarly, we posit that infection tolerance may be a key antiviral defense strategy 
in bats. However, infection tolerance is likely not the only mechanism at play. For 
example, in addition to enhanced flexibility, the expansion of type I IFNs may also point 
to enhanced potency of antiviral defenses by providing more mediators of potent antiviral 
activity. Adaptations in potency are also indicated by observations of lower viral loads in 
Egyptian rousette bats compared to humans (Amman et al. 2015; Jones et al. 2015). 
Finally, even with mutual disarmament, the host must be alert to viruses that may revert 
to be pathogenic. In either case, definitive tests of these hypotheses await the 
development of further experimental reagents for cytometry and biochemical 
intervention—reagents that are being developed now with information made available by 
the completed genome project. 
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